var title_f32_21_33104="Clindamycin: Drug information";
var content_f32_21_33104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/46/41704?source=see_link\">",
"       Clindamycin (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=see_link\">",
"       Clindamycin (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9275 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-EFB8DDA1F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33104=[""].join("\n");
var outline_f32_21_33104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/46/41704?source=related_link\">",
"      Clindamycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=related_link\">",
"      Clindamycin (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_21_33105="Sturge-Weber syndrome - bilateral PWS infant";
var content_f32_21_33105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sturge-Weber syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral port wine stains involving V1 are present on this infant with Sturge-Weber syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33105=[""].join("\n");
var outline_f32_21_33105=null;
var title_f32_21_33106="Giant ventral hernia following open abdomen";
var content_f32_21_33106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Giant ventral hernia following open abdomen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mature skin over a giant ventral hernia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33106=[""].join("\n");
var outline_f32_21_33106=null;
var title_f32_21_33107="Acute eosinophilic pneumonia PA";
var content_f32_21_33107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute eosinophilic pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAS4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UpcUlOoATFGKWigBMUYpcUtADcUYNOooAbg0YNOooAbijFOooAbilCk9OTS05Bk0ALHbyyEeWhbPpWla+GtYujiCxkY9eqj+ZrQ0C2Z3QhWbPQYz2r03QEkiZCUKnGACMUAebxfDvxVMMx6RIw/66x//ABVTH4YeMwM/2BdEeoZD/WvpPQt7Ko2scckgV6DY2oMccb4G/krjnrTsI+Jpvhx4uh/1mh3I/FT/AFot/hv4wuM+R4fvpMddqg/1r7H8W2bQWnneWu1mOGHTOent/wDWqfwKguYZUYBW9wfeiwHxfN8OvF8P+s8P36/8ArJuvDmtWjYuNKvoyfWBv8K+5PEcTQghUYYGe9ePeKoJJ5eQcjj2osB82yWtxF/rIJU/3kIqIqRXoviPTpAGbyjjPXbXA3CbHIPGKQyvijBp1FACKrMwCgkngADrQyspwwIPoRTgSCCpIIOQR2oJJOSST6mgBmKMU6pFCGF8sFdSCox94d/8fzoAhxRg0484wMetFADaKcaT1oATFFKO9HNACYpKd2ptABTu1Np9ABRRRQAUUUuD1oASiiigAooooAKKKKACtDTLUzyAkZUH061XtbV7iQKmAO5PavQvDOjRxxxs2GI6jb1OKALvh2x2RhY0+bvXZ2KshGU/Oq2mWLI4KqB2xwM10dlCARlFI+lMR0PhuUiZSrBfUV6jZW8TGCeZjLznZjAyCOTzzXn3hiw86cbVIbHTsa9M+xXRtYl2RpGO5IwOfTrTYGR4iHmRzGRNyOMEFcr1B6VH4KFravJs3I78BQMqOT09KTxXIy2S2qToXjXIJGA5LZOcdsH36VgeHpLy3nV2QFSw6OCCM57H+dAG14puA5YEnHQHGK8s1qCR3JYcepr13X7aEw+cEO/aGCnkc155fW3mTklS5Hr0FAHlms2hk3I6/LnnHevMvEWleVI7x87eoxivetStvLclMEnnpiuL1/TEmRy8KHd6AZ6UmB4meDSVs65phtrmUxghB2x04rHIIpDEooooAKKKACSAOSegoAKKlW3lY4CNx7UzY3YE0ANpKkMUgAJRgD0zxTSCDg0AJSUtFAAyMEDFSA3Q460yrEiYt43zndnjHTBFV6ACn0yt7TdGluCrBSwP5UAYwUkjAqzBa+b1DA/Xiu30/wALxvDtlBXoVI5wff1FX7fwpKjhsb1Pcc0AefiwCkCdJ4z2IAYH9a1bLQPtChrSaOZjn5Nw3EAf3TzXqukeFBPbgTKRGe3c+9MvvAHlsrWjSYzxk8g/UU7AebDw9G2RcRvG/qhGPyqtdeEroBmtMSAZOCRzXsdnod8H8vWJYpYiDtbgyD8QMH8a1YND0y3Jkhmeduc/Mpx7YHT8TRYD5suNOurdS00LIqnaSeMH39KqV9I6rpUOpKUng24BCucEr+HTt6V5trfw0voHMmnh5oick5BI5osB5virNvbtKflHpXQt4YntWb7av2dE5YuQO/c9KyLy8QAw2YZYcDcXxuY/4UgL9rPZ6egGTNMcFtpG0HnjNWf+EuvIk2WkcUQ7FuSP1rl8nA5PFJQB1WneMtRhuVaZ1lXuMYzXrnhnxbp+oIplYRSdNsmAxPHTB6V8+RnBwcYPqK6nQ2Z75GCsCxAyoBFMD658KxLcTI9uxIHXuRXpNwY4bRSA2R17mvG/hZqX+kJtlDYOCD1PSveUYtGCrg5GMihiPFPEk119rkuJYXELyMELDoAe46jqOTUug+VcHGXDEjAXGD6+9aHi23mtNRxEzKwdickc5I5/E5NSeG5pzM7gRPNkAMAuRzTA19ftfIitoifk8sE8gHp0/wD115X4w1e3sSUkZdw5xkACvXvFdylvbtNdMnmIi4XIyT9PrXy/4uv45JpHnO0HoZFB9e1AHH654xvJJmMVy8cZOVAjXgdqxU8WaiSVlui6HvgAisjVJY3u5WEjvuP3iKoMQemfxqRm9davPLKftflzxnttXP5is2a3ikBe3bC9drHke1LbmKSIhi4cDjOCDSwrMzf6Nl2x91eSfwoAoNGw7GmopZgFGT6CvUfCXg8eKMB4nglxkhSPm59+K9E0z4YafpQSZ0aeePnbxtznqfU07AeN+FvAl5rMK3UpENmTw4dcnnHAPPX1wK62HwKLKIi2tvtLDB3DDE/1/KvSjp5SQSA7cdB0ArM1LU1tyVtVBk7y7QfyosI8xvtDgtsS6q4jU8JGmNzde1Uxps1y4/s61EFseN7qrO3HXnOPwr1Sx1CeYCK93zxHplt2Pz/oa3dL0TTppFeCQrL/AHXYdce/JosB4Xd+ELiCDd9nduMlsgnp+dYb6JKzHCHgFicjAFfTFxoTjI8tWUe4z+XWuc1TSBJKyyxBiOmBiiwHgE2lSLkqpwPWootMuJFkZANqHByele23nh6LyiEgA4I4xxXHeINIfSo/MsrhkncFSNobjj14pDOJ1LTpbTSNPmmGBMZQuCD91gDn86yK63XLa7l8I6VcGKWSOGS5Esqp8qEyKBuxwMnpXJUAFe1eEdNiS3WJgADjB7mvFa+iNHhUbCD93BFNAa9ppCRtiNewPNatnpcjOoVSM+nFadmVUR8AnAzmtqQ+QiuGChlBJPP4UxEdppsNpbK9zIXlz9yM89O/pTtTkDWLRwIIyBnruP8AKqQmlMuVYqp6jv8AnVpPmjYtx8p6n2oA4bWEnJYeY2GGG9T7Vm6cXt7jerbe2OxFdXqFsXdg3pmss2Hzk/w98UAbGmxrdna42kHpnr9K3Hgt9LgyWQMepJyWrn1uo9PtzdTMFKDCDOMmua1Pxa9yxM5EhGcOCPl/AUAVfiA1vq6yW21UB7kAr1z07V41e+Fbu3bCvHJnnMbb8D3GK9GvtXhuBIWuY3wctsYEjJ9BWBPPFHLujV2bYACW6Z9sUmM4JNPkcfK67u4PFVNvFd+l9K7IJYYG2gfMy7j+tZkyWF1eKJ0ETE4YocLjHXnNIDloYmkkCjvXT6SLjT33RMC46svOR9avQWWmo48szOB8wA2nP8quabZ28c5y0gwQOVA/qaAPWvA90W2yAiKQ46/xdPavo/QJWNmvn3ETIB8oBAxz9K+ffDGmJbQ28uG2bto/n6e/617hpaNJYxCMbBypJbnk8/1/OmxHJeJdPlubm6lS4zvJIUuMjn0pngSylGp/vHiWNXGWZ8Fhnt78Vbiiku9aljKsRJITj3zXS6DoSQTSMQw8skAdsnvTA5rxKXvJZ5QRhW+UnFfOnjyw5aV3YkAsATjcea+mfHEwghZYkyMDqc55r508ViabUo4lBChQTuXJ70AeJ3lsyMcfNzj8ahhtnkBODtHU13k2ihZCkk03mZLFlCoMEfjTdPtglvi0c+cDhXf5h/8Ar/CpGUvD+gC8tpNsKvzgMc4GB6/56V2WjeHobFD57/IONsZAH5kZNSxyzQ7czOSOwbJH1q4b+bysNsdc56DH8qYG5YXcto6iyKeSpzsz2z6//Xr0PQdZt9Rtf9JZYrpf4CeZOe3qa8Yu9dht12qw87uyEMF/DrV3StQf7WlzFOrseSQf6dqYj0bxOjSFjEAin7wz1Pqa4a5gLyYxx0Oa7XR9Rj1eJopnX7QehJ5fnp9ar3Gm5yQDuHH4UAZOi6eTMg9sjP0rffSvsgSVW3AenarvhmwjnufLlyAB2PqDW1qNgY4GjTPyHn1NAGRb6hc2sWSnmRHqDyCPpUrW8N6j3EIUrjkZyR071PaucCE9Rxg96fZQfYb55gT5EilXU9qAObvrRGZwvysBnB715b4pUr5zkkDOPwzXrfiONrS7fkH0OevArzjxDGZkk+7znJP1oA5+6tUPwa1eYglllAXJzj/SFyfr7145XqWrau1p4F1vRpGiVJGjaHP3nJlDMB9MV5bUjCvpPSUOxeOa+bK+oNIhJjU4GDjBFNCZ0+iKHkXcM4A71t3K+e4jx90DH1qjoMH7wZ9K1UQmRnI9sUwKlvATxirotx5DH0FWba3JI4q+LPFiEQMcDHzEkkAdyaAOUmtDK+VGc1FdWsUEMk821YIkLnLY6V21rpi+Q8kgIA4571wXxLv4IYFhVuoZiATz9fpzQB5d4r1l9QkeRN0UCZAXOTjPYd65AXNzdqIbctCcE53ElsHua6MQPd3GFHXOGY8AZ6CtnT9GhWNWZS0mec5wP8+9IZ5jcWEsfmtG+yQH1Ixk9fpVq0RmV0uSjfIBuXJI+nY12+r28UbMu9VwMADnHPpisQxxpNlIizNwWGcH+lAGLb2EE0snmXHHXqFP65rUj0G3fBijU4Tgs+e3X2pdNl866EbWscbY+YMef88ZroY7GSUp5K/7JUrxQBz1j4eDTRuAy5H3d5x09a7rQPC0N2gwiJJnG7Jwa59baaKQG3hZXGSSCeOPWvR/A8ksEy/bY2YbeoJz1HegR6R4f8JAWVskRiUoSSrs3HT2rubfTxBaiJXLkdMnFWrbabeIqCAUHXr0qWi4zB0jRTDeNd3SjzMkqC2SOetbwAHQe9FFIDjPGWmlzuCkxBc4yfWvINds4PtRnaLJIxt3HB9a+h9VZEsJnkjMiqPuA4z2r5813UIo7ieDcpw5woycZ96aEcheQIHKhUXng/Wsk6d5dvJIEQnPHy8j/PNXNb+2mTZHcC3UsMMOuPT2FZ98lzIrRJNuBfPDHp+VAEM80dvFtKgEjBbHJ469OKyJtQVpfKgDRp1DhsknvTNenkjQrC8srMxUlZCoxnn61l215JFIVfZKWyOc5+mRQM1lsy7s67WcgjJYjv1qTSd0d9lWKyLnk5Xj/OKjivFaQRruRmJLNyVxnpn/AOtWlbwM8HnJl42JBIyR1oA6LSdT2TIyuFnBDcHGTn+des6VJDrNikyEC4RVDgt1PrXgkKFZt4JUZ4B7fSvUfh/qQUhHJ80FeOctnsaYjqorZ7W7EkW5DgHA7e1aMtw8yctlj1JrdFl9ttI5IwN+0Hr1HpWY1oYpRxgE0AYcsTBtwOD65pxld02Mc4weta9za7QSRmsi6Ro2HXcKAG+J7RJbSCQ8kx4z615rrVoBGy44+tet3oWTR4uDjbu5PrXDa3HGYmO3p3JoA8K8eQLFp0pPDZAA/wCBCvOa9X+Idqx0i8lJztII/wC+xXlFSMK+r9AjJgCgfdr5Qr7B8ORAbh6gU0JnQ6KuHyRgAda0raPdIMDim6XbkI5UlSB8px3rV0yHKoxGCQDxTAmtbbJ5FasdqZEAx1/lS20BwABWxDCFhUDqeaQGH4jkjstMJJ2gqQBzzx0rwTxTG9/qErvk9ioyOMDFew/EK5aW7SzjyBEMEjuSASK811yBLB8qVeZgQQf4en5n/CmBy4so7Uq8x2sOiDktyMf/AK6Zc3jSjES+UgzlASW69+P5VLd20lxc7ncoDyWIPPuBT7aONdqn5pOcn1GaAMiW3M+MIw8zoxHGfrVa306VZGMgQITx8xyfTtXTLDEWeKQ7EHzBsHCexqIxRHAeT5cgZXJK/lQBiW+jrvFwpCzqQGIycrz9O9dXpH2VGTcx5IbJHAP4VBBApL8SOgAPA2896lsbdJLjZMwQLjnrj/GgDdt9DtyZFtUaZWydwzjp6enPeum8GaIZtWNtLGVXYSrHPBxms21aOC32Ws7pLwpAyOMDnIrtvA8zf2wFk+8Y2H3T/kUMDvVUKqqowoGAKWiipGFFFFADJY1ljaOQZRhgivl/xn4fvNG1+ZbtgIyA8bZPPJHp7V9R1wHxd0mLUNJgk2Dzkfhgeeh7d6aA8GubQzFWDAycBsg9KhvNOFrEWMiqCue/UiukQWsRRSzFwMnC+3Tn61RvoBeb3XeycjBGOg+tMRwF7YEqQiqzNnGWI/GqB0l47glYlDDjOTyT6Z7V10McLxkl5N3PLRnFW0srcyZcndgEcUrDORTS5CxJRypO7JBxn2q0tu9rEnlgoG4Kg9BkdRXVyQSLAzRxkleAAOtZVxZCVTtyknOTzj8aBFG1kjlkjRvkkzzjOG5/Sut8NRGOf5htbA5GeOa5m20aSJwzMWUnJ2jv34zXW+HHVWKTdT0c9fxpge4+Bp/tmnlWB3xBQ3P3vf8AHFXtUsTv8xQME+/BrmfAF0ba9RHJEb/I349P1r0K5hDKQRkGkByFzHuiJxyRXP31vncGHBrrp4GDtkECsa/tsITg+3FAGZcYEaW4J5iwPrjNcN4lVkiWMcE5Jx6ZruNTJjuYyOCFX+QrlvFkCi9kA5A4FMDxv4gI3/CN3+T/AAj/ANCFeMV7v8QIc+G9RJ7RE/qK8IpMYV9neHo8SD6V8Y19s+GIWIQsPnbqB2PpQhM6u0j225+latggwuBn8KghgIhwQPu1esk5xigDStkbKiNBnIyTWpIRGhb0FU7CJioZTtwTn5fvcU/UXdbNiXAbbjcB3x1FIZ55r0224mGFadid5Yfdzzx71x12kexvkV2OTkj7v+FbeoSubh1CDODn/E1zOrX8duSkOJCQRvI6fTn9aoRmX/k25BvH2jkgYO7nt+tZE11kt5AXnorDJB+tLfZbczDk5JxzkVlrDOZsx43dBxjPegC5FLJKhEigZbBXB7Hr1q7bxMFykSspA3Hbn8qZawvEC8zjhlyuM7smuosrK0aNQ0khPHyqBxQBXstLh1K3YQSESKd7KAckDP6VuWmixl0kWINlgAV6ZGOPwHatbQdJhhcyxCJnHy4brgg9fWuz8OTW3lW7S2qpzgKYwMAj7x5+vNAHK6t4UMezyAzFYxl1QjnHI+uavfD+weLxEAzODDC7EEY64GPzNeiXoxbSNHAszAEheBu4/nWV4cW3klmuIoFikxsY5yTnB+valcDdooopDCigc0UAFcv8QUb+xfNiOJVOP+A9/wCldRVbUbOO+tXglAKN1yM0AfOekRLcajHEVJR3xvK881uDTJpdKuXjTYkbFT8uR09a9H0TwlFYXLebbQS4cHcUGAB0I9+K3NU063XRbuK0toUHluwVEAydp/8ArVVxHzBDc+fDJGbQQzq7DDAdBjaT9T/SkktpBMfMAEmMbSOF969Am060+zkG2i81W3OQAC31PftWJqFgZJFIi8uNwTnAOfpQBxUzTxyFIQMjIAU85Bp0Es7yIk0Qk2Mc7Vxx/Wunn0FFkUqUzk8YA7+tU3tWhYggIWGAByOvegC3ZWKS7PIYGQ4zHtwyfhWrHp8W1VxhsDonNYVtA8Ehlbh2Iw3r9K6HT71blgkwRXAA3gYyPf3oA3dAlaOeO2faJBgofp2z/KvY7dvOtYmPVkB5+leJ2iMZgzquPY9P/r17Jochl0m1YnJ8sA/gKTArX8fzdP0rH1CJTGwA7Gt7VQwAcfd/rWDentjGRQBzGtx5lU99oz+QrE8Uwbm3rjDf44/pXSauDuV+wQEgewFYOpoZdJgZu24frTA8h+IMWPDeqHr+4c9K+e6+jviIhHhrVABn/R5D+lfONJjCvunw5Fgx5xkkfzr4Wr7w0AEPEEU8EAsBjHrihCZq6hfyJcNbQuUI2AuFB6sM9/SumsbdmhRpFUNtBYDpzXEeJ5pLNvNhjJMewADGSobJ2g4BIGepArstEENxY2kkyTxGdVfypSMgkFthI7jBoA2Yk2PEBGDjOWJ5HFZetXKsXReVHHH0rYkkEUTOf4QT+leb6rqhFvJEu7zW4PA4BFCA5rxfd/6S3kAqnRiO/wD9auOn3TEuI/lIx046dRXQ3TRF3EhLNg8Dkf8A66wL+MJmR2wq5x79KYEcFuMsOCg4Zj1HNOEKRqzOu5MggdOM4z9apT6lbLxhhjgjIyc98U8I32dLgYaFidpOD+nagDVtZoCCPLztHTaCcZ4x61oQSmB/NWAnkHcRgH8Kx7JYn2hlOcjBwMj8a63QrOKRQssrKhAOAen0oA29E1e5hWIwafArEAsjqTjPtuwTXUWWtrFIEvBbB5AFUbApHHyjrWXodtdG/QQQ5CgKGCDoOe9dHceGrTVp4by7ia3kT+FABuA6E8daQE+ma2Lm2CmMqEPkmTPUgdufpWrYpsRwUVSWzkEHI/Cqmn6FZWMYSIOy5DYcg8gY9K0RGgkMgUByME+1IY+iiigAooqOVJGkjKSlEU5ZQoJb2yen+elAElFFHOfagApHXehQjIYYI9aWqOtQyz6fJFAMluGGQMjB9fwoA848U28djqlzHYQxeSuMtgttOBx1x+lc2jtNGS+QACWC9T045r2AaWj6JPC1rH58kbAbVGc445+teYPaEtLlRCYiQS4BHp1+uKoRl3EECyDcu3cxO0fMWPp7YqsLdiQ8UW8Hgl8c81YvLUwYZmkCvkjkdRWXcpdeepwUBPGerD1I6UAXHtBMBvi2bTj5O2Paq1xprLEsiBTEvJIPP4irYmdiEuQQFHDLj170XLSRqrcYbgFe3NAD9HvVk2QEEscKpxjp26/SvYfCNzusEgb7yAfnjmvGIIlkcSgKu0cYAAJ969J+H10ZmRJOJo/lYf3lxwaGB2t+m+FxjnGR9a5K6bnbgZBwa7OZcxn6Vxl2nl3Lj0JHWkBR1NcxsfSE/wDoNc6y+ZpzqR91uPxrptXQhcAcbMH8q5215EyEdVz+tMDzX4iwf8UtrBx0tZT/AOOmvl6vrL4jRD/hFNb46WU//oBr5NpMEFffXh9R5cW3AHB6YxXwLX3zoTYhQ9eBQgZrTaXbXt8Lm4LsUVUVDgrwc9O55/yea6GG280R5J/dlXVuMhh3/H/61Y1pJl8dq37WTCKM8mgCLWp1jsZFdsjaQScDPFeO3t9s+6xYnlm4yc9a774gakILcW6sQxwx/KvDPEGuLahoVcmXHzHI+UY/nQgLmq6okTyEuzPz90DA+v8AhXPXmovcSOZfnX1wAf8A634Vhz6jcSP+5DSR5IYZA6gd/Wtu1jhKAufMU9OcCgCrGkkrABeSeGAHX3rT021eObEkoIYjPTmgkBhtBAHOOufSpIpN5TAbcScZH0oA6ews1eNAVPpx6ZPWu68OadFHtMVuWO0H5lGM9x9M15rp2ry2UwjRsdAwOB6/pXoWh63dRMojP3tpAwCBzyOTTA9S0ezW3to3aMRzFcOFIwSe/H0/U1oVQ0W7+12ETsZCxHVwMn8qv1IwooooAKKKKACiiigAooooAKDyOaKKACuP8QaRbpNcfYosvKpeRSRtA46DHTvXYVUnSMzSOJlWUREDcRgD1x/nrQB5PqFjPcAojJJtOBvAyR+I/wA4rLuNIKFWmZjJ1b5lIHPbHavT7yyhimaWQZUfd6AE/Qc4681lz6faFg1sTvOQdxG7qOnt9aq4jzSayLMWVihHygZGM1QDSWrh92I8ZO7BzXc6lpEexmDgAnJYckc+g4rmtYsBDnJDREDABBP5UAJBdRSoDCuw4GRgY/8A1V0/hPUobK5hd/8AWA9cdiP/AK9edfa2s9pHB7Zxj6Vv6fdpcPFKpOchSB2oA98lnUW6SA5VsY/Guav40+3S7fu5yKn0u/F74c8xW3GBgG6dAKrrJ9ohZ85wxHH0pAZ+psPIfPLFdtc7EoWcg9wRmtzVztx781hSPtmQnoTTA474ip/xS2uLjrZTj/yG1fIdfYvj9N3h/VBz81rMP/HDXx1SYIK+8dJfZbLg8ACvg6vui0fbbAZ9KEDOlsH6H1wa34H4BJ6cVyeny7doPqO9b6S/dAoA8++J+p+RPNKu1mB2ICe4HX8K+dLy4L24lnuUmnDMcBiQR1x09ea9M+Lmrk6tcW6MCiNwS2MnGf514Xa30cAAnZpM9FDY6j/PNDGdPYXDT+ZKsrkgZKsAMfz4ratNTmEebdgHIK5C7h+tc3DdLOci3RAWPAc4/wDrnFdHpPkSjbjygM4Bb72enNAF+GWe5KCR3D7iCA/T9Kv2NntuY97seccngc1NbWDF1ESB8EncpODXsmgeFdO83TLKWx+0pPCZJL6KV+Gxn1wMHAHTt1oEeYWsk9sSLZ9rZ+8CDnn0rqtB1iRZY47iOOUkDDoApzn2FWxolqt7LDFslCyFSf74BIyPr1r0Dwf4YtLVTLIsDnCkKpzj680wOh0S2EVrDIkzurRjC54Hr+ua0qBwAOwoqRhRRRQAUUUUAFFFFABRRRQAUUUUAZHiaee2sGnhDFEGXUdx+Vco+oAxPPGpLzYidSeBlQPy/rXoRGQQeQeMVg6posIW5lt1VMxMSp5UnB7ducGmhFGwF2NJCovmB2x5jv8AKqg9vQVStoltbwNdOJScsjdQDnpnuK29PvBDZwW11sYtkMWPABPQ/WqWv6aoCz24ARc5GeufT1oAybrVLeaWWOVBGm7B3txn8q5PxGuGMkQ8wsOqtkdf1qbxDcyK4jY4VRlRu45P/wCquRvb10k5OU6Fd5wfwpgUtUiSZEZvlkGAD2/GqWmXstnfKx4ReoB4bIq1fX0Mwwo+b+JN3J+lVWeMQhNw9cbupoA9e8Ban+7ngZwYZkZl/BMj+VbmiyhYrmEnj5mHPb/9deW+DdQ8sxQF8SLJlSD1UjBx+dd3p05Nu3P3cgjP4UAS6w+8tgjArn7xyACOoNad04lXdu7H5c1h3cnye31oAzfFh83Rbvn70D/+gmvjWvsTWH36PMucny3HX2NfHdJggr7ftmPkqK+IK+27c/KtCBm9p5+YVq3F0Le0klJ+6hP+FY1g2OT6VF4ou/J0duT8xxj14NMD54+KOoKLyRt26SU56E4wMf4V5IjknJJJJ5JJrs/Gc0l0W3MxlV+feuJjxleCTn1qRnX6NLIw3fvFX03Guw0u+gk+SWAs3UHPI964vSZVGFYnI7Ac119lcL5AFugG1zkoufSmB1GnNLBMu0nyj0Yk4/Gu20jxS8NsdPN7P5XKGFJn2DJ5GPzrza3llGImaRkfuSRjn0rbsdNQMZUZ1VM5JB/CmI9It9QRniWFFaPcC2cqX59a9L8HwAJLOs25GVQI8n5ep59+f0rw/wAPpeyTxYMjopACgH5uemOxr3DwRZyWtjO8yFHlZTgnnABx/M0MDpKKKKkYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBJawNGytChB56fjXM3xuVuXJcfZSACjcbT611tc7rQyWeKNhLESHRCSGBxjIxTEee+Jg0c2Joj8y5VhyMA8Y9utec6zcbGKMuGx1Fep+ISPNkIYALhduT8vHSvP/ABBFDLbtsjxLjGfT1NMDg728nj5WNwR0xxj/AOv/AI1LY6gt1GoUnf06Hn3qDWIpYtrsWbAx3wfrXIyak1u2yIuPQgn5TSGeleFdTEHiCyEpJVGOfQgrg/zr1uxYJc3EAYq3IOSe4xXzp4evkmlhvVJyjeWwz3IBzX0BJMP7US7T7k6BsZ74Gf1poQvnNGCG/Ksu6lBVue/er2oyATSFQcHkfzrnb+fBYdM0ARXkwazuE3DoffGa+SK+mmnYyyqScFTxXzLSYIK+1rZjkfSvimvtS26+9CBm3bPtTr1rE8ZTFrJVBwobB9uDWpAc8dAK5/xTIXtHVT8w+amB85eNWePVJUiXqwYkZPbFcykSgNIxIA4+Vc81seKb0Ta3dMrndvCjr02jmsy3usJtdS4zk4X2qRlzTJIzcbyxyewJ5Fd7osLojcNtb649q4GG0Al8yF5Vwegjzj8a9A8OSzsm2Pft6fOCVPT3oA7XS9LguCiHMbgDpziux0nSo0G05MKk8nnd71keG47cMvmMF55K5O38K9F0a209I9jbnZhjd2GT0FUIf4d0e0uLxEtI5MoRmTGNvXmvSbO2W2gjjDF9ihQzdSK4+yvbPRXRYcb5H2nIPAz29vrXZQ3EUwGxwSRnA5pMCWiiikMKKKKACiiigAooooAKKKKACiiigAooooAKpakoRFmXaGDAEn6irtRXcK3FrLE5wGXGcdKAPPNdPl6g6DLRTNu3KckEnH9Otefa9AkDsELKhxuUg5Wuy1ExxXb2cwYGJjslGckZzxXl/i3V5bW6liJaTI25YnOKoRia1tWEK53k/dYD+deWa9D5Ejm2DOmQMAnIOK7C58RIG+zy7ZARnzADw2Dxx1rktVn2uLiOc7GOFjYk87euaTGR+HL82t9CrOREzDeOSPrj2619PabIZtPs1P31Tv8AjXydpv8Ax/I4O7HJ+mK+mfBd8b3TLGQnLKpjf3IAP9RQhM6DUFB5znIzXJaoxDHrXX33BYZ+7xXJaoAzNmmByd7d+Xcx4PfBr56r3Dxfm2tXkXsQR19RXh9JjCvtGzbIBr4ur7M07JC0ITNiJtsbH2rifGF+LWPOQZGHyqa629k8qzY9Ogrybx7qby24aOISZONpHA60wPEdYXy9RlRmLuD8zsME0tqyiA/L85J/lUeqP5l9I2MZxn8hT7C3MjozAhM9fWpGdR4ay8/zAbdvzA9Ae3XvXpOmxoXRPLDHswT9TjpXAaFEyzoqYK4PC/1Oa7nT5YrW3ZpJEEznC89aaA7HTrY2zKxk3OxwFVc9xXYWWoLbmNRksADlhwOR+teY6bq0QvYiztJIThQOvXH9a9L0TRdS1Vg3kGGMnAkYAHGfTPNMRcmaS8nmygAGCcjlc967/wAEWMlrYNJNIWMmNuR0HpWPo/gUQJI0147NJ/Fsxt5PTk+1dTb6NbwWKWqPIEUht2RnI70mBqUlQRwFJVfzpDgAFTjB4x/9ep6QwooooAKKKKACiiigAooooAKKKKACiiigAqO52i3fe21SMZ9KkqjrQZ9PlRFySMDPQmgDxbx9feVesQw2gld2O2eDivNfEsiX1upLE3CAMp2kAjPQ/wCNdR8R7GSFbtpDscc8c87vrXkt9f3M1tvt3xDCAQxPzMfb2psRg3ME4u5Y5EkQ5yDtxn/63vWPqkoUiM8JwdoXGOK6HUr6C+VZCTu2gY6ANzniuO1GYsxjIA2kAcc0hlnTpRFIo4LSHGMdAe9fQvwznD6exQ/KJSwGOmVH+FfNunkfaEB4B6H3r3f4QTloLxGJ4G8E9e1NAep30mSW6gj0rlNUIDHHvW7NLmIN65rmtVkzIRj1piON8aL5mmTDvjj8xXhde3+LJALB/wAf6V4hSYwr7N0sjYpr4yr7I00kQ56n2oQmTa43/EvYd68o8RGKaMpIi7d2QScc8969P119tuAOu3P615P4mJXzfMIC9iSAAKbA8kvoyl9KZFOMgkEjuKFuDGwZeFAwq8enemajL9ov5XXJyQB68DFa/hzRHu5Y5ZEDJn7rDg/WpGaOhG/u8JZx7FZceYwGa9D8PeDN5Mt28sjEgkcAZ7dutX/C+horBnTAxwR3r1DQtPjeQIy45z1ppCE8FeCbBbmOSOziEg+YvsGevr1r2XTtOhtYlVFGBz071m6BZpGq4ULgdvrXQ9BQMTpwOlFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCAykEA59aKgvblbaEs34e9AHm3xO8Lfb4JXVHII4KkAjnNfNni7whqtivm6dbefAi4IXG4D6d/wr6L8ceJJ0Eoim2KvYgeteY3PiqMMUuHHzEAAAZJzTEfNt9OWl3IzfKMAHgr7VUmlaVt8h3P0J7mvcPFul6Brkmy48iG7I+V4yqvjnH8+9eR+IPD15o0haVfMtSwCTDGDx+lIZj8j2r2L4L3u6e5GeTF8w9wV/wAa8c9PSvRfgzKya3dr/C0P8iP8aEB7rcSgIV+tc5qLhXY1pXMmAp9RXNa9OUjJzVCOQ8Z3QSzkGe5/pXk1dh4wvfNdlVshj7Vx9SMK+w9NuIxGR5i9u4r48oppgfYmrkTRKEIbjHX3rynx7byz26xW8Zdy2Megwa8RoouB0kemSW+p+WciRcH1wcV6d4T05o7aIMDuPXPrXhtKCQcg4NID6+0yxLsylnCEYxwBj8q7HRLZ0wXJJ6bvWvhVLq4T7k8q/RyKsLq2or92/ux9Jm/xp3FY/SvR/wDVr6/StQ9K/MVdf1hfu6tqA+ly/wDjUi+JteT7mt6mv0u5B/WkM/TXNGa/M8eLvEi9PEGsD6Xsn/xVSDxp4pXp4l1sfS/l/wDiqAP0szRX5rDx14tX7vinXh9NQm/+Kpw8feMB08WeIB/3EZv/AIqgD9J6K/NofEHxmOni7xD/AODKb/4qnD4ieNR08YeI/wDwZz//ABVAH6R0V+bv/CxfG3/Q4+JP/BpP/wDFUf8ACxfG3/Q4+JP/AAaT/wDxVAH6RUV+bv8AwsXxt/0OPiT/AMGk/wD8VR/wsXxt/wBDj4k/8Gk//wAVQB+kVFfm7/wsXxt/0OPiT/waT/8AxVH/AAsXxt/0OPiT/wAGk/8A8VQB+kVFfm7/AMLF8bf9Dj4k/wDBpP8A/FUf8LF8bf8AQ4+JP/BpP/8AFUAfpFRX5u/8LF8bf9Dj4k/8Gk//AMVR/wALF8bf9Dj4k/8ABpP/APFUAfpF71y3im/RCF3H5ewPWvgb/hYvjb/ocfEf/g0n/wDiqrTeN/Fc3+u8T65J/v6hKf8A2agD6Y8dXc0kkpHAPTA968zCPPcDKt8hBJPWvK5PFHiCX/Wa7qrj/au5D/WoDrurE5OqX5PvcP8A407gdvrsBnlZiziUHIIOeOat6Dqu+3FjqJEgHDhh7cV5u2qX7HLX10T7zN/jTPt13/z9T/8Afw/40gNvxR4efSrgvCS9q5Gxs8jIrsPhXClvOHJxI28YPpha84fVdRkjCSX92yAYCtMxAH0zRDqmoQMGhvrqNhwCkzA/oaAPpi9f5PpXHeK5vLs5G54B714+fEOtHrq+on/t5f8AxqGbVtRnUrNqF3Ip6h5mP9adwF1K4M0rDJwGOKoUpJJ5JNJSA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior chest radiograph of a patient with idiopathic acute eosinophilic pneumonia demonstrating bilateral mixed alveolar and reticular opacities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5WRGdgqKWY9ABk1N9juiMi2m/79mtHwggk8Q2qMMg7+2f4Gr0WLSYnOWj2/7tAHlQsLwni1uD/wBsz/hTxpl+elldH6RN/hXrqaRsHyYKj161cgWFQN0G4jrmgDxgaRqR6afeHnH+pbr+VP8A7D1b/oF33/gO/wDhXucUlssbhrNtpGCQ3H5VqRwWUqFYnaNs5UScc/WgD54/sTVc4/sy+/8AAd/8KU6FqwGTpd+B727/AOFfSR0vI6DnuvehLAINpAKn9KAPmj+ytR5/0C7/AO/Lf4UHS9QAybG7A/64t/hX0hc6Al0DJGAjd2xxVCXRVizGV57+poA+ezp16Bk2dyB/1yb/AApPsF3/AM+s/wD37Ney63pP2VwhXIblT6isv7GT1/AUAeX/ANn3v/Ppcf8Afpv8KUabfHpZXJ/7ZN/hXqK2pA5FWbe0JbOOKAPKU0bU3OE069Y+0DH+lWE8M68/3dE1RvpaSH+le46JYNnODn3ru7G2EEOCcsefp7UAfKw8KeIj00DVj/25yf4U/wD4RDxL/wBC7rH/AIBS/wDxNfWkK4OcZz2q6g3KCcLx0oA+Px4O8THp4d1n/wAAZf8A4mlHg3xOTx4c1r/wBl/+Jr7Ejz0HKj25qaJ8HnBoA+Nf+EM8Uf8AQt61/wCAEv8A8TUZ8J+Ih10DVx9bOT/4mvttVEiEAAjHFZU6gMRtAI/WgD47Hg/xMwyPDuskeosZf/iaevgvxSwyvhrWyPawl/8Aia+woZAhWPHDD5s1a09iwZQO+RQB8aHwV4qHXwzrf/gBL/8AE0w+DvEykA+HdZBPTNjLz/47X25IgZQqniqskOwgkL9KAPi3/hDvE+P+Rc1n/wAAZf8A4mkPhDxKBk+HtYA/68pf/ia+yLh+CD9Oec1kXt3FFnzCAfVj/SgD5MPhPxEOugauP+3OT/Co28M68v3tE1QfW0k/wr6dm8QWUbbS25fUdqhuNRtpNuWADdCD1oA+Y20LV0OH0u/U+ht3H9KjfSdRTG/T7tc+sLD+lfS1zaQXceEdQ/UCsa400q2yRAy+hHBFAHgH9mX/APz5XX/fpv8ACnJpGpOQE0+8YnoBCx/pXtz6Gd2+2BKk8x9T/wDXrqPD/h3aFeWM+aentQB85J4Z16THl6Jqbf7tpIf6VJ/wifiPn/iQavx/05yf/E19c2enJbAtgbyO3arDWgZlbbnaOKAPj/8A4RLxISAPD+r5/wCvKT/4mmy+FfEMQzLoOrIPVrOQf0r64uZfsa4AZnx1x0qg101yAt3Ekq54HTFAHyrB4W8QXDlLfQtVlcDJVLORjj14FSL4P8TMMr4d1kj2sZf/AImvqu1smhlM2nMA5XaUkQNwevXiuq1CWR5TdpqE5jknc+RHGqnZk4CtjgjjJPXtigD4pg8I+JLguIPD+sS7Dh9llI20++F4pZvCHiWCIyTeHtYjjBxueylAz9StfZ89lbxx6W91CkdsrN56xS/e3YIJGc54JNZOtCM+UuqXDXN7kmUo4ZMZXaWx1AXcNoweetAHx4dB1gZzpWoDHX/Rn/wpg0TVSMjTL4j/AK93/wAK+0Tt+12JjzIwD+UhmXKxlT9xhwi5/hbcfes3XLNmvWkaeWSZlG8SMrsuBgAuoCnjB4Ax0oA+PX0rUEzvsLtcesLD+lQSW08SlpIZUUd2QgV9Yy2TEMSeOua4b4p2+PBGpPk4Hl7R7eatAHgNFFFAHSfDuPzvGOnp6+Z/6Laval04AjaPrXjvwrXf490tcZ/1vH/bJ6+jI7FXILYDdCR3oA5xLHDYA6npVk6ZHIMMNrdjjmt42SAgsT9c1NHAgx8nPqTQBz0ejyE4IXy+mSOtWZNJMa7shh39q6a2hLkgqauxWAYZAwPSgDjbYTW7AQZxnBXqK3bOAXce4oqTDorcA1YNmkMjBYwSD1I4/wDr1BNFIxBZjkdPQUAWDbNFhFIwOvHWoLixWZcgfN6+lXbOQsm2Uc+verqwjqvbvQBxOq6WtxEIpR8wOQ2OlctLpjRSMsgww9uor1q5slmTGAGHesq+0pZl2uBvHRhQB5nJaYbhc+1aunaVkgzKQMdBXQf2K1tLmVMv1GemPWrlvY8EkZA5JoAZp1sNwCrhF56dK10VAeSM+9Z0l0kETGNwoH8WOvsDWW+qhA7qThc856mgDqN8YO1QS3t2p0U0ZYKXz656muDPiCRlKsxJJz/k0lpqMrvxIyEdCDQB6RDJET8sgz71aiwW5AOK4y0v5H/1h+Y98frW7YXhyMtkD17UAdNGAUwoAGKybsFJG6cdzVy3nV/uNx6VBeRiRhuJBzxmgDJuJgjli+09Kv6NJvY4/MnrSf2ZHLE7biSDkAVY0qBY5gMnHXFAGjGM/NyM+tRzhlZmLZJPp0H0q8UVQOBgnpWRqcz7mWIDGKAMHWL8W4ZYz8/Tce30ritXleQNvcjPU1v6vhXYE5bHJNc3qDK0R3naPrigDm7h9jleOnPOc1LbSRSIUYEFRlee3pVS6uIA2AS3PYdKqC8SKRT5ZJB596ANe3vHifAldMHoeQa6fS7lrh0hkCvuHy4Oea5SG2W5kXeHiUnO4jP6V2Gh2cUaEWjoWz8zvwQKAOk03RwriTGXJ4PpXQxWQRSVUbu+Kg0aYIio3I7v2rcRNwyD16Z5oAy1hLHJ6VFOc5WPOO9aF0hC/LnGecVRKYJz/wDroAy5IDzgkYJOTyOabsIGWwQPmAArSaLntz7VXkiw5HbvQBACee2egzV+zmbZtLZz2NVAgKgjB+lSxZUDqaALhtYbhiNvlufQZFUbjRlR8h1x14qXzGX7rYx6HFSQ3h4Rzx+hoAoLYJEuERcE56daFt88Dj9MVrbQy7o8jjoaIERsAgfhQBg3UYJ8sgY/rXB/GC32fD3VnHT90fp++SvTZrf524zXDfGqLZ8MdYyOgh/9HR0AfLFFFFAHY/CElfiJpJHUeb/6KevpqCE+WGyrf7oxXzP8HRu+I+kAjOfO/wDRL19T2Ee1yp6YoAbHCWHIytPjsIg2FZs/3cVbCnOB29KmO2FcnOP50AECRwrhucdhTxKvQdaqM5c5J47ClGSMGgB0mXbOcj0qvJEO469qse3GKcRk8kDvQBTSLY2QADnPSr1u42jd+NIsR6v19MYAqVVxjB5oAlEYYArjpxT1thIu4rz2NSRJ5qmNuBjGRwavbQFwOAP0oAx57JCMSgFR61yXiK4mijCWyMYj36fn6V2Gp3iAbAA3b/PrXGatFNK+8vuiP5D8KAOXvLgZVJZ1OOoXnFZeq3sUUARVdi3PJwMVtalZxv8APEvXn5elc1q9jOWjOOOmc0AUkvixIWMAdsGtCyuozywZSfTtVC3sgHHmOQDxhRmta3gjUARAYzzjmgDcsJXIBiKuB1Of0rorSbG1ZVKk8DPpWBZx4hyoBYnqOK07WZlJVju46Hk470AdPp+BJwcH/PNXb4sr7QNwPcGqFhho9y9Mc1cvG+bOPlx0oAfDJiJDjox71ctEAn3IOo71jRXBztKfKeRzWxprlicrjAoA05CAuPTpWTqH3G2nHJwa03ztGRyRnOKzL5SNx2nBORkUAcRrSybmyAAe5rg9aWbfh2LBugBr0nWISWZm4zx7VxOtqpQmMANjr3PNAHIvauQeM+1OitHAG6InBFaFrbzzN+4QsDx9K6DS9PEThpP3kg5A7LQAlhYSSiMyIyR4HJHJ+ldBaxlE8uJdqqMBcdT70xEkZy218Zx7flV6BjF13ZxzkUATWc7R9GIJ4Nb1hrMciiCUAr6j2rirrVI3LRoen3jjtT7OVWK+U2PY80AemxMsiBlIZD3/AMahmtjklFyuM89qxNKvJIyGDHn8q6WGRLiPMeQw5wKAKAhPTHfNV54MtkrWwY88jg+mMZFQTRAngZoAx9mACFLZPbtS7Nwznr6CrkkQC9MVEq89OMUAVnjz6Z6dKieI55z+FXmiJ+62OCBkZwe1DxewzQBXsGKOEclk9T2rRaAoxOODgj2ql5fPI/CtSzIlgKNyydD6igChJH8zHnB5rgPjguPhfrfBH+o/9Hx16W8ODkYDCvPfjrGF+FWuY4x5H/o+OgD5HooooA7f4LjPxL0YDP8Ay26f9cXr6rtRnnGMCvlT4LqH+JejqwyrecCPbyZK+srWMBQMdB0oAsRooO8n5VFU3JlfP8PUe1Xbk7Ylj6FvmYe1VgoPPpQAwJzTlQge3Ye9SDAZVyQzZwPUgZI/KpQvNAEJjwRjn3qVI+cj86cV59v51PDHz/Q0ACRAZ6YHPNSJFuPPTuasKmegH49qmCD6IOf/ANdAEIXy1+bgf54rPvdRChgx2jtipb653sypkBcDpj8R61zuoyKo+Z9xJzz2oAfKxmJIHXnNVTGA4yQefwrOnvWt3zIwRD0Hcj2FEGqxSY8kblz1c8j8KAH6jaLPzHmNhyeMggGsHVNOdIW80qADkEc1vTztNHy5I/SspPNSSbzWVkLfu154XAGDkdcgnv1oA5TYqkszx+yrn+dPjQMQqsP5VtXOnW8pO2FgWOSVqB9IEWGWQkgd15oAltDLGArAYxzg1tWabzkAegBrDhtJQcrKpA7EGtjTwyyAZGR6HNAHSWCGMoUJVTxitueIMc4XOM9KzbDnuTjv0rckXIXaAAVA/GgDPjhjZuIxnFalhCiZUDt0qO2hG4tgkDqa0IIgjH2FAD3UFVxge1Zd1HuYkjJ962wuBzyKoX+2O3aVRwB+RoA4PXoWaUruAQVyt3BaRgBmLMedp71v6vNJPLIBkg85PpWBcQSk5C5B4z3zQBQeUghIVEQ9B3q7ZRPIrFmOcUQ2Bd/3sqqF9OTV0tbwx7Vd/MYZ6c4oAhkcQwl3ZgE53g1l3GpyzBjFK6KOgB60y/ZZlffK+OgAXjNZM3lrGQs5zjuuKAJRqtwr4Lh+edwBrSstViZgHRo/9qPkfiDXLCJmbETqTmpovMiOCN3uDnFAHqWj3ZkTMcglHqDgj6iun067w4wwB9q8n0S4KpvV+p4IbvXZ6VqZIAnG7H8Q+9/9egD0eF1mj3KRn0oZN4OQc1i6deEFXRt6e3UV0KlZF3oRyOaAM6ZMrxggVVKBF6cj1rVlh2s7bnO85wx4XjoPQd/rmqUkZBYZ5IoApJIzJ8y7G7jOR+dSMuevJHfNPC4OMGhVAAB6epoAj2gMTn61LaEpOrZ9vwoKgfxZb3owcDjnPSgDQaNXXHGR2rzr4+QlfhLrxxgfuP8A0fHXorHKbhz/AFrz34+N/wAWi14HnHkc5/6eI6APjmiiigDufgiM/E/RR/12/wDRMlfW9qoUZOCe1fJPwRO34oaKf+u3/omSvraBicfXrQBHMd8zEjpxzQAc0KN0jHOcmpVX86AEVBuG4AnqD/WplXpTVwOxNS7QR74oAZGhLe3rVy3jI649qiiQ5wetXogPwFAD0XAx05yeKgvZBGu0dTzVossaBnPJ6D19awNQugpZpD16L3P/ANagCvdzcMdwVB3Ncvrt7sA+zjGT989RVnUrsuecnsB2/CsPUVeSAsQVA5560AYt3MWdiSS5OTzmobZ5EkMisV460tzKEG6NfmPHvVCS5ZTmVhGncMeaAOrsr6IoI5uWxkGr6yI2DGF254K1wa6rDG67d7+hzgVftdVcyfu0CY9KAOpumIjIwS1UQZDIpBJUjGc9KpxazJI5E+GUg5I4Iqa0voXcRuQsg/v8D8KANi2jDKuMD1q5aWolmCgd/SqyzKZcknJ/KtbTw27dgD3oA0bOJw3A+QdO5FbzJ90DAwMc+tZNipaRSN2Djt0rphGp5I7UAU7bKFlbAyOtX4Bvc9gB1pqwo5HAq9axhSdq4FAELZC49B1rG1HOJIyNquMj610sydQOD3rn9VQoWbr60AcDfWzK7bh8oPeqNyqCEvIRGq9Sa09WkjXdJI4CjsfSuN1fVopyURjhTwP8aAK093NdTNEgZUxjHdh70jTJHwGzjg85P41SMrp8wI3EHp/jVETgkqOHP8VAFnUJoEO1pHRiT2rAmuYlmG6ViOm0r1q3qCsVMzyREJww6H2rmp5/Ml3Ae2TQBrLcRPyJ0X0UnBFXrTeei7we681yruGJOfpmr9i8kW1kdlf2OMUAd1amJ4lDYGOp6HNbFiWDZjkJ46E81x9nqbblW4QTDjkcEfjXTabPCy5gcmT/AJ5scN/9egDqLC7aOcbXII9a7bQtQWQbScHuOxrzyzmV+GU++/qK6HTmaMhlJPt3oA7/AGgrg8elUZlK/KeMHrmpNPuRNCAfv49afIBKN6diR3GcUAZ7rhs9D3pMY4/LmrEg4Py8+9IqBiGoAg2HI9PTNIyjvU5ADKHwMnA560koHT0oAniJaIbutee/H0H/AIVFr3XgW/X/AK+I69Btxlcdf61wPx/z/wAKi1/j/n3/APSiOgD42ooooA7n4Jf8lP0X/tt/6Jkr63g4XkV8k/BH/kp+i/8Abb/0RJX1tF8qE4ycYyKAGRgH2z1qyF9elQxDBz/I1MDz6UAPCnB2gE9gTgVLtx/+qmoRuHY1Ix5/DtQA+BTnHGzrnvmr0a5HAAHSq0IzgDI96tM2yMtjGBQBV1O4EMWc8emeprir+V5JWK/MxOSTyK6LU5DLXOXQ3ZEeMdz6fWgChcSLFz95z39Kxb25hjINxIckfcHJP19Kn1HUBHmKAlnzzMf6Dt9a5W/lKMe79cGgCvqt48chEGyOJumOv4k1z8gkMrNkuf7xOc1qTbpRgjC9OazLmAwsCkhPoM0AQpPmPIHzdcH1rU0+4WRMbhuPTJrOjkRs74xkn0q/Zv8AZyjRqODngDmgDZjI83YiljwMim36MWOM47g9vf6Gte2nMtus0a7hkdKbbS7ZSJcSbicAjOKAF0a8aNAsr5HRQf4a6uzuZETKMWJ9axFS2KpiAZB4YHBxXR2ESSKvlkBscCgDpNGZnRRnD59OK6sHhcDqMEiuT0ZT5yqQQK6tMZUH8xQBLCmCPU9quwryOPrUNuvTODiriLg9cf1oAbIMZ6VzuvAmN8cnHSunccHIzWTqFoJSQV4IzyKAPF9ZjSSYpJk4OOtYN1pMW0yAM5/iUnAA/wA969O8SaGU3T2/DAfMuP5H1rjLiTykyF3NnBB/rQBzF5aPI3ysqIq4VBzj3zWJd2hjUSSSADB6Dp+tdhKYJ45XTMTgfMOxrjdddvmSNgBnkCgCjLbNcP5jS4jKYBY4rn2tykzh3DRj7oC4I/HPNblxxZwqTltx4B7VSaINJkspLDOM0AV7e1UgyOzY/hq0kRLARuc+460jPltqMvHHBFTW6jaG3KAD8xzQBatleEgldx9ewrSjnBwoOT7GqULvHMW+8D3XpWhAqScyIFY85HFAHR6RqTbhHODKox8x+8v49/xrr9OlztkjfzI84yO31rgbOEI37jLdiTxxXRaXcNC6lCdx4I7fjQB6Pp83KN0NdCCGjBXof0NcVp9xvxtABHYH+Vdbpc3nQlCfmAyKAEmUbs8nJxx2qAYVzntWg6HocZNUnXmgCI7UOVUbsYLHr9M9cUwnnj8afjnA/Co3HTHfvQBNb/UHiuE/aBK/8Ki10Ac4t/8A0ojruovvYPSuF/aB5+EevEdP3H/pRHQB8bUUUUAdz8Ef+SoaL9Zv/RL19aZIQjHOK+S/gj/yU/RcjPM3/ol6+sycJ9KAJIsHIHb2qVQcnOagiJHJOasxt6DBNAEobH4nBqVASwz19ai2g4zx68dangXJ7UAWYuAKZfOFUKSOmcZqeNct0461n30m522n260AZl2PlYbz1J+Y/dH4dq4/Wrv70cZwnf1b/wCtXQ390pBijPB+8fWuWvIQWYzAbsnv1/GgDnrwPIxwSB3Y1UcRiPrvfH3n4/Kr90WchFBJ/uKO1YV/LFbvukYu4/gU5x9TQBXunG0hmyeoxWe5JyW6eppLvUDKCAiIAeq9RWdMWcBtxbPWgC40kYIAdcdhU8N1Ggyylm/z2rHdXVucgYzSwNhh060Addpt6u9znYGB4Hf61v20AuAkqyqueOTzXFWU5WZSpK5BBHqKvLM0XypIY03ZABxQB2Em6E7CFUg8EHmt3RJTtBJ5rzuPWLlW2yBXx/F0NdX4c1ZZFzOpUjgY7UAer6M3mGM4HTmujt0Fc14XZXiDhtwI4NdXGRtBx+J70ATQxgMasKCeajiAAA6/jmphyefyoAHHHt61WmAx157VayMAAc1BJyOv60AYGox7kIwD+FeR+MJIbC9kRyMN8wxXrmryfI/JC9OK8D+ILifWZArZCrjA+tAGXJqZMm3BVHzjPPPauXuw+8g/NnnNXPm3HERJ6gHtT5rKRirqgKkE5z0oAzWX92ynICjtWY+AWPbFdHdQmFZEBRhjGeTzWTLYSALvkQMTnbjrQBmbRgk4HoO9CscDPQdBVia3YOQj7vU9BTGgCYaV93+yKALFndywMGjchu3cVv2N8shH2tcZ/jT/AANc4gO/iMgfmRV23l2t1IY9Ce1AHd2eDCWgAlQc7h2HuK2tMIZl8zjb0I6ivPtPuGjdTDJIr9mHHNdxpF0ksQS5KRXH94DAb2PpQB1NmXiZSDx/errdHu8tEVB64YelcjZsykLIMH0Irb09/LuEdW+XvQB2zqGy+T0qtKmH9R161PayBo0II6UTqQ/HQ0AZknDZ6CkKgYz0qxKnyk+npUJwwoAavXjGa4P4/kn4R69k/wDPA/X/AEiOu99s1wXx+/5JFruf+nfH/gRHQB8cUUUUAdz8Es/8LP0XHX99/wCiZK+r0J59PcV8n/BTj4m6L/22/wDRL19Wox2jIANAE6YyCcY6ZFWo+gH5VWj5PFWkXA7+tAEqkkgDoatwjHfntVaEfMMmrluu4njGBnntQBMSEj5POM4rA1CUqNijJPWty6fbCfTHSucvCAXY4LE/lQBk3X7vJBG4j8vpWFqbK0BeZlRB09T9BWvfOiLvcZx91fX/AOtXKajO8km+XDdhjsKAMXU795f3cY8lDyQp5b6mucvNpTamQ688963NRgyCyfLg5Hc1lXVjMcPIuMjjB/lQBhzEKcqcj6U1RIVDLnHXJrRnSKMZMYyeCD3qtKS6DA7cDHSgBhdZwscx2lRjI5qeGGIqE3AHPDY61R+YNyOfpR5m3ncAD1FAGxFCIpULjPPr0rRC27NyNqg8k84NZWmyRPE5Y7XTpjpVyKRxfOpXcrjAHX8aALz2OVDKAeST2FdJokKAKNhOcE471lQhksCrAlutdJ4btxPHHhsEdPrQB6R4ZT7PZr/DurrYeQCB161z1lEUWJOCVHODW/aglRkAUAXocAY9T1NTg4NQQjI5GCPWph90etADxyfSoZgQD6U9QQOc+/HWmyjsf50Ac14hPl2UrAjcRgE14JrKO95cSNuLjPIGc817v4rJ+zkA4rxTUQ0MtxCcEdQxHSgDk1IllIkO0AEnPFSM5jQKpYhMnIHYVBerErgpIZGc9BxUeoef5IIIIxg7c+lAEaTloJCFAVjgt3P0rMnkCE4cswzj1qO9dorFEjOATg1j72Zm5I7CgC27ux29CKbjnJY5HtzVMuyjAY+3vUizsMFsM30oA1IDsyzHr0APWrqBZHyygn1/pWPBNtOZACc9BWxp5jkYGSQxkcjI4/SgC7b2537ouV6BTW3p8gBCyghhzj1qnbgLwGBGf9ZjIrTgjQBfNdG75oA6XSdQKqI52yvRWPVa63TGI29CDyPeuAtomwDHhkBznOSPrXW6Dc5URMSFyACetAHoGlONqr6+/StGQFo+eo55/lWJp0hWRRnGCM5rcdgGxnOaAKrrkY9etVWXaxHWrsi4yAM1VlTLDpQBHjAHPB6V598fgR8I9eB/6d//AEojr0PaOffsOteefH85+Emu5GP9R/6PjoA+OaKKKAO4+Cn/ACU3Rv8Att/6Jkr6sj7cYr5S+Cxx8TNGP/Xb/wBEvX1ZG/zYGaALUXNW0PA659qqRgAknvjqeB9Ktx8EENn69qALUSjgsOhyMjvVqAEL06mq8Y46GrcQOcDg9aAIbp8ZyfwrnNQdUR3bgLW5dOHY45965bW5NzHbyoPIPrQBzepXJZyz5AP6VhyiVgSrDBPXsK2ZrffkyEgdl71QmSTIREYduRkke1AGcCY8hckngnHNZtzE6ghehOQSelaF88cBIMnmzDqqnhfrXP312875Y5UdAeBQBXnnhHErBnz1UVnlwXzGu0Hjceanl2zHLLtPqBVW8iMYG3LAjpQBDc2k6vgsCOzA8GqrwSYIwSRVtZpFj8vG4ZyBmpYXckMVVRnoelACaZZXMwPlqdijrjNanl+SIHyQxAySD71uaFJdRELEU8sLkAAZx71JPCt67uGwQPuE/rigCO3kndcI6t6gc5rvvCFsojgaVCrDn5q4C0gKgiIEn1BxXo/hkSi2j8xjyAAGoA7ewYs249e1dHa/w9T7YrlrFjgFDkeldLatlVHXjrQBprjA96fwBn371DF15BIx39am4YEH8hQADr2xUcxAB7cd6exI9MD9KgudwTv+VAHM+JmTyjuUe1eSa9btNMdqAgnnd0xXrusx+bgZGD+lcVq2n7y4jIU/T7xoA8uvNP2zllUYHIOOKq3VnMohZR1PIx613i2Um8JIAy54yvSnPpOZChj+VTgjtQB49q9ssTyhmZSD8qkfmc1iFVIxH0z+de3eIbWyns/skQgaRAQdyc/XpXll3pbxTMsJVlzjAB4oAxPIyBjG7rzTysajC/MehJ6Z9qum0MIx8rN/EQc1W8h25I+X0WgB9uEQBup9u1XEmwxOzO5cHPpVREI+ZkwB2qYAgAHJJ5FAGvptysGdnKkZIPT8q6KxuLW6bZEvly4/1bE4+oP9K5YQtCirMCHI3YA59q0tO2+ao2Fs9SxxQB2enNJAQu0EfSul0yMbvMVcEc4HrXKaVf8AmKqXGAvQOOCvsfaut0sNAqg9xkHqCKAOo0yXfjBIK9feuqiYvbqc4rjrT5WDpn3FdXYPui+negBzg9/zqvIvY45q5IMc44PSq8g9QPb1oAqE7e+K88+P5P8AwqbXc4/5YD/yYjr0NyVOOP8AGvO/j9/ySbXsf9MP/SiOgD47ooooA7b4Mf8AJStH/wC23/ol6+qoMbhnGcYzXyn8Gzj4kaP/ANtv/RL19U25wc9aANGM89OPX0q5BxgYxVGMkkAmtGAAYDA8+1AFqPGQAOAKsqdqEnjAPU1XiU59ulWJceUxB9KAMe/cqrdieAfSufmQqv7xixx1/rW1d/MxLZIHAHr71h6is0kUqwOqTYO1mG5FPbI70AZNypLEBQTnIPT8a57VLoYeO3ZyxHL+v0rZvbh5IFindc4wzrkAn19h7VzuoKoUlSAgH3h3oAwJl2H5mP8AM1TuHQYwfmB44zzV+VGdwEUgnPPXNVXs3bLECNfQ8k0AUWdpMqBtPrnFMa3kCDYCQc5Y9KvLboq4OM55yMn8qXcPlK5JXt70AZbWh9SDnqKmjskR/myQeR2wa0rVj5nzp8p5J9DWhFGs0m+VFEQ7k9aAH6LELVIzkANyynv9TWzFMJ5RiNFQc8LWJdyQbgkUqnb1X/69bfh795buj7SAQyMOcA9jQBq6ZaRM+/CqxPIA611mm27L95eh7Vz+mweY6+Uw2g8ketdrpEO6Ib8Zz3oAvWURD5I69RXQWkeMe1ULe3fCbNp5wc+ntWzAgA/woAlXO0AYzU2cA5pkfRc5qVRwSBxQAxhkdx/SorpSYjwM1Pgc0ki7lIoA5TUd3nDoQe2KyruyEq71HzD2rptRiAIKjHpWS4KklsrjqfWgDkruP/SEGzJJ5I4qy6xKAWT3b3FRazexwy5TGScZPbFVJLvzIwSFHNAHNeK4WDCWCMrI4PA7/hXJRW1zJGPtMZjkXIIxjI967TV4ZbuZJUBKqfvk4Uf59K5zVdRea58qCRSFJVpCPvkcflmgDm7nTU83cCoBPK5ziqc1uI3I+9j24q/d3lwlywmWNlXjGMiqctwowsq7foeTQAwDc4VIwcn+7k1IlqivnIjl9+g/Cn2uppGxWFgDj+7zTo5Y5nDsmcnj5v60AVnt50kLySeYufvZzVu1Dl8DBPfuAKuxzICFWGPaB7nFWliinclUEWepTjPtQBd0yIkq7YCg8DPJ/wDrV2Gk3WT5cmNh6YP3a5CK3EY+Q5UnqecVrWJ8vb8xJ9e1AHeWTlHUdq6rSOI+uVI4GelcRpU4lUAZ3KK7DSW5GSRnrQBsSYKfSq7jIGP0qdlzuzjPTPWqzEorZ5x6DNAFOcBSc9M5rzX4+Pn4U66Ov+oP/keOvTLtiVZexryz47n/AItbrg/64f8Ao+OgD5HooooA7L4QHHxF0g5xzLz/ANsnr6ot3BUeg6g18q/CRtvxC0kj1l/9FPX1DavgDGKANq2OT1HpWrAPQ9fasm07VqwtkcYoAuwYwWGDS3BHkNg89c0lvjH170t4G8lSABjJ569uKAMK6GTWBqc7fMoVSPWty7dYoztGMcAAdK5e8YENIVJx1oAybjO7kEZ6Lmsy5j8xmd23Adug+lbFyvmjLn5McjoTWTdM7SfIPlXhVX9KAMuddr7lPbqBWdM2SN/T2NaF7IsWS3bjaDWJfXDSZyQgHYdaAElZVbdkBh1APNQmcBJNgSMjncTkk+lUmb5WznPr/Sq/mHdnGeeaALwnmwZCzMh4z0Gas2Fz8xjcZWTg9yDWbJdySRbBxGvSMDpT7Jym5kJIx1PUUAaEkIDlWzkH6g10/hASfMqk47etYOhSvcyNHcp5iAckjqa9M8O2cEdis8aZ3ccjp2oAu2FqjM8qsqHjccdDXW6MX8kBvmGT0rAgSO3SRlIAxzWvoby+VgHPoG/xoA6uzYEhfQetake0g4wcHB+tZdgJMDeqhfUH9a04N5HzIB75zQBOo9BzTpPMELGBEeTIwHYge5P0pEJ47nsamXvQA04yQMYzxSEfIeKcSegJpG4HQ4+tAGbfIGHTk9xWFqKMiMR87fyrorpSSeOSePpWVdQkpkZyOtAHBa9bMtm8rRkcZU9g3vXMabJcXEZEqS4yOdpORXourWjvC6oM7uqnkGuYt92lu6xgqzcYYZAHpQBT1B4rWxKzuh3dAcde1ee/aITO5AVsE52jr612uvvHdAq+FGPvAc15xqVm1tfu3GCMlh0+tADbvzZlby0AY5we9YE0UqErcZ3ds1qx3kqlo1c89/Ws+acicI6kKT1I60AUWkKkqgx6kU+3dlfKkCpZkg83puB6EH+dKIzGwLKCDngD+dAGtp98wUiRdyH7x7/nXRWsYlZTbyAr1Cgc/SuQidz8oJA9PSr1tcfZpAUfc69weBQB2lp8shDKNmcEEZFX4oiMmJSFU8g9fw9axLDWVuSou1RD/wA9VGB+NdDaDa/RueeDxQBq6QxV1JyO+TXcafIfLDKCfYVxUKoXDRj94BkjFdTo83Kx57DigDrW/wBWrDHI71Wl5Jwc5/wqeP8A1QyG4/Ko5BjFAFGdQc569K8u+PYx8L9d69IP/R8derS4wcmvLv2gFH/CrNbI/wCmH/o+OgD4/ooooA6v4WEDx5peemZP/RT19O2rD5PWvmD4Ynb450s+hk/9FtX01YuWCEdKAOls+i8VqwKMZI596ybMnaM56VrW+SBxyaANGAHKqTzin3eCuOOODjnH1pIVw446Cn3f3CeDgZoA5TVW+YrnAHFc88WwAFiyjjLHJ61016q4LZ+b2rDlGWPA4BOT296AMSaPMjbMknJYngY9TWFqmojLJbMABwWArR1y6Z0aOMZhPfP3v/rVxV7IcnBwQw6dKAIrmTIJOWJ71lTBh6Yz61akuCi4bac8jA61CIWuE+Rck9PpQBDiQxN1J7VAY5GXAXIPHPArUttOLZ86URj0HJPtTktYemXOP73AoAzI4GVwFBLd62LGwLh1lRlI5yDjNWYljEfICntnrU4ZyqKgGCeDjmgDU0SyjRFdlCE8ggEiu+hgktLeNAGwRkH198YrC0C0ZbVFZXcgZYdq6C5kmZrdQoVVXnf3+lAFW7ul2rEVySfmJziuv8Ko8kZMiYOOlc9Bpy3EolwTjGB/Wuz8OxeWpUnPOOe1AG3bqcdOnar0YOB2/CoYkI/wqwq5xzk0ASKMZ/wqVTxTFHINSDnpkelACYPPHBpSDj5vT8KXGQfSlHTJzn0oApzjGB+NVjDnORwavSgHleAahC45OBQBl3FrySoGK5bX9N3fvFGGHOa7eRcFuv5daydRjR1PB3H9aAPHtQhJYxs2STyCw4NYWuWKNZnaUHZuxNdt4zsFtoGvFjm3KcnAAIFYOmix1DSZd7MZguDuHJH1oA8+XTIZJ9nnbe+Se9M1HSCkgEk6s7n5AeMjtW9d6WVut1v84XOSfSs0zbVMM0eY8kdct+dAGALF7cM8sahfrmonkJBxIOe2OlacrvG3ls27+6o7Cq91bAxBgoJbr6/WgCCJ0aPAkBbHOBU0KCPrjgdM9aoMvlZZfnx6danhuN/3Rtz04zmgDVtJAWDEAD+VdfoV75aKkpLxY4PQoa421kVpQcgHuBxXR6buABwvB6qOaAPQbIkEFnGwc7sjBFbtr8squv44rl9DuSIxHLgIeh/u109ouJVBBAoA7S2bdAjAnHWiXOcN1/SodM+a0IIBAP6VPKMp+PIzQBTlFeXftAf8kr13PrBj/v8Ax16nNyMdPwryz9oHP/Cq9cyO8HP/AG3joA+PqKKKAOn+Gv8AyO2m/WT/ANFtX0npLksi559K+bPhp/yO2m/9tP8A0W1fR+nHE0ZB70AdlY52LxWzbjgc/mKxtPOVHHPr0rbthkUAaMK9AM0zUCPIIPQ9alhHA646nmoNWbYFHqOfWgDnLhX8zgcmuf1t1MbJE3A6jP3j/hXQ37iJCc/Me57CuH1WfY7Z24x2PFAGBqbMpYlwvXjrXP3UsMjAmMtkZ+U4rdvoTPuKZyVyR61nLbxxfdA8wfw9t3rQBkrbxMN7B44x/e5P5Ug8tU/d7mX16VbkI3t5xTYeu0VRlMat+6Y7T1OOKAHFwWDH5MHnuKnimSaQKHAbu7DArMndNoXeB6kHrUSReYcmXKj88UAbPnWqtl5d46ExDr+NdLp0sSRK6IIoh/ERuP8A+uuJt4YwigF1JOOB1rqvtMTLBboWXGAFHc/TtQB0NnfvJchYGbYOcd2+tbuC1uJA7OR/tdBXLaTG0U8oU5AXHynAJ9K3JbkxW8cYIJC5JoAvQ6i8BEZcuF5AB/Su48OXcssYd8cDp0rzeO6Fw0NrDCic7mY/e/PtXofh9xGEAXgevWgDsoTuQGrKc9RVW1YMgJGKtR8Hk5yaAJQOeOfenj8DikHXOPenD1OKADPbv/KlAx70c8dz6Uv160AQSD5RUG3HNWpR0OMfSoG6n060AQN94Z/TmqNzbhxgjA9K0COcgEc1Ex2EjHPrQBz+oWKXELxSxhkYd6801LRX0ia4aFMQucbs8AHtivYblmyFCIc9icVg6vbi5gnhKqydOR1oA8O1AGIkxHL45xx+lYV8QjCT5cjqR6+ldJ4mtbnRbxzJCJbRidki8bT6GuNu5Ek+dGyHHIB6GgBt1dQSRAEDzAenc1XSUPGWVeB1XBJFVvMXcFkiJwf73SlKFgwgc/NwQev0oAmcMHDbFIPI96XykmfcdsR9VPT8KhtpSXaC4cYJ69atx26JJhW8wjv0zQA8xtAMqC3o/Y1uaTKVCmRQQR1PBzVS0QSsyhWAPVSeGA/rWlFYlSXjDYGOO9AHRafdbyNwBPTpXZ6TcedEOcsOh9q8/tJtjLj5D3x3rpdCuyJxgnjrx1/GgD1DQ3LQuD0HTmr7AbGBxxWRoTgE474ArXfg4OR3xQBTmHy4647V5V+0F/ySvXOnWD/0fHXqs2cE9a8q/aDx/wAKs1zkdYP/AEfHQB8e0UUUAdP8NOPG2m/WT/0W1fR1hkOvNfOPw0/5HbTfrJ/6Lavo+xXGznOPSgDrdPPyAnJzgcDP410VoOK52wPCnp7CugtDgcnmgDVhGQv061V1fnaxPAHWrduePWsvxA5S0ZhjduzkntQByOr3e+Qjdx+lc7eK0pIJG3rkVqXK+czbjgZ5NZsuIxiRv3YOOKAMGYlY8R5BJJ561nzxtMrDhW9uv/162NRRF3SB9ynoucE1zd3dNA7SJLiReAq9B/jQBnTgJG8kjqi54BHJrNnu2ddiSbV7gDGakvZZLlvnHsDj86qCEhgXzg8YoASOISuBvySeauxWhVC0mAnQY5pIBGqGTYdoyMZxSNO0hxjCDoM0ALukZtsO70rotAdbT99JmSYnByO9YqTtGoK8A9gK2tEtHnuVeT5U7lhwKAN+0uWnvMRDagXJGMc1swxbztZRhh1qjYQ28CkxYdS2N3pWs8bm5hCsSijOPagC1pGmKL9pcjYfau70qDBBydvpisDREZo0WMfLnOK7PT4Nh5PP8qANS1UCPnrV1V6DjnkVWgXCjAH4DFXEzwOmaAHKDnnPXsaeM/TFJz+PrTh6UAAo9KMfSlA9qAI5eozjGRioCPTPHU1Zf7tRFTyOc/XrQBAy446ZqGSPngdatlTkcYHvTCuDnqMUAUZYw2ARgiqEiEucqvz9q1ghKYc5OOo4z+FVngBY9sUAef8AivR4bmKRmjDQupDrjOD64r571rTLjRr10fLKSSknZh6V9Y3lpuLjg4BGD3zXmPjbw0t5azROu3+JSR37YoA8M3pOpVwPNXjOaghkaGfa5/8Ar1PfWUlldyQyod6k9ehFVirZEe7PHDZ4oAfOr28+5BkZyrAdvSr9k5aQN90AgtuqKzuJQVikVWVeu4dPcVLht3yuQrHmgDagOWDR52k54PWuh0qYR4LgsewzXF6dctDNsfcFPGK6KxmRxtV8ODwCelAG+6qVzAg3HmtPTZcIgIbjpng1kWG9XwwIJPBI5+tasMLGTegH+1jvQB6R4bnDWa72AO7HNdLMcAE4/OuN8NSBI0jIyrDBB9K68cqoA7YoAqzdD15/SvK/2gefhXrZHT9x/wCj469SnO1m9TXlv7QJ/wCLV63zn/Uf+j46APj2iiigDp/hp/yO2m/WT/0W1fSViOE5xXzb8NTjxtpp95P/AEW1fSFgWON2AvG3B5989qAOsshhQa3rdsJ1J79KwbLO0YBz7VuWnOAQOT+BoA2ISfMT7uzHPXOf8Kx9ZfeXUMMDitYsEjZueBgcdKxLw7twHJoA5W/AhkVE285IB6n1wPasa+kVVDSnc5/hFdFqYijj3yqpkAIQ4GR689QK4fUJ23ySSbsqMAds0AZeo3zJKVypGOcc5rDmCEM5UKueCO9Xr4ltzN8oA59axLnzJCGAwPSgB7urqFjQbyc7vQVFGEXJdOSeveliVIk3sCW7DPFRgtKy8nB74/lQBMQjIpUfKGxipo7VGTcY2RScAnmn2cO6QhF3KM9a3YLULbxvKdpLY45oAz7KxXzV2k7P4ie1bLFIT5YLZY4K+tBhReC6rH6kdfwqWC6t4kEyRlpz92RyOB6igC7b27Iu1m2qCPbHtXTR7DhlYtgD2BGP51yBkefflmDOclj3Fb1gx+xg7iTjAoA7HSrkCVI44x5aj6YrrbKUOFyAR15PSuH0eV0jRXwTjuOa7DS8MV2g8HvQB0MZyBn9KtJzyQTj061Uh6Z61bi4oAmHJzSgU3B6Dg/TNOHB9hQAv4Ud6MUtACHGPrxUbHk+tSHAHJ/WotwYnaCffPFACHjAFMY/Lgj6088k8Zx6Ux+OMAY7UARjAPyjBqFkBPGKm4BJznNRSDDAgYOe1AFK6izjrmsfULYyxuo79Qe9bs2QM5JzWddfeBHagDxTx74TW58+W3/dzLyo7N7V5isLBAvkBWU9Vr6X121SaMuQMj0rxvxZpptLsyx5AmJDegP/ANegDkZIPOhIRP369WHeqVszRExtzg556g1ovEdxeJsOB93PBqncQh5iSmDjODxigCSWQxnc/wAyN0OKu2xA2ypls84BrPhnjKASxludpG7FXIGWKIsgI+YEHrigDsNMuQ6qJNyseOTnFdLpimR1z06DtxXBafNuceW2w/xD1ru9JuP3CgcEj5SR2HagDrNOyjLtOFHT2rsraUSwIwIPHNcRYSAQAk/e+7XU6NIfKeI87ADxQBPdnDMOQDzXlfx/P/Fq9cBPP7j/ANHx16jeH5cn3HNeU/Hw/wDFrtbHB/1H/o+OgD5EooooA6X4cnb40049OX/9FtX0lpz/ACKfwr5o8Ats8W6ex7F//QGr6L0qZvLywXbxg9/xoA7XTjkAgfSt6yxvU+grmtKdXQFSCD3rpdPwSe3Hc0AaEsm21we9Yd3IoO9mOzbk5rVunBjCr78VyuuXJ8sKOVU4/H1oAytXuC8pYYweB3ArkNWIkkBU7SOntW1eXiujKWy4GOKwp3Vz9zOOQD2/GgDBuwxBQj5gck561RdBu5BVPcV0dxBHKmQRnoQOufb2qrNEIYiZVAkJyny9qAMaa1aQggEIvCgjr70+K3IbghiavSRu8W05AHzEnjFQyyhFUptOF7cYoAtF4bSJUXPmZwT1FWjeiGBVDJvXk57CsG03TTrucHJzuJ4FSX8u27IjKkg59etAFu4vXnbc5Ij9OhY1JDMrcMxLYwF7Zqgoluh8uflGCAO1XLOH5iZEdgD2GM0Ab1i7NAQ2DsGV/wAK29PZ1jQu5CYyQBWJYxlpFjgiIDkcH+Gt6dHjuo4IjuSPG70+n+fWgDrtNRZgssXyocY9RXW6amEB5JPrWD4cgHkqCvB5we1dPawkHB4xQBqQZKjJq+gwF449qpwIEwB6dKtxrhmPPzds0ASL7Y+lOHYUncd6UdRQAvWl9aTNKKABv8mozUhyBTMHINADM9c9qY44PHtUoH5Z5pH9cCgCA9CRnOKibGQSMGp2wBzj3qLA9SfegCvKDtP8qzbkAhiykDHTPNakobBxjNU54ywLAc0AYF2waJlABGOjV5v4qtlkSSOVTh/ukjpXpd9HkNgHIrjtWhW6do5MZP8AF/WgDxW5BtZ5EZc84PHXFWI4ElQBlG3qAD8wNT+JIJLS+Vjkrkq3HX3qhBMcBkZtwPAI/WgCLULCRULwp5gDcHHf3pmjq0Q+z3BMhd9zsegJ7D2HtW/bTG6gAcbSvBI4p4063WISiTy25O0jJb6UANtrf7K4G7LDoa2LK4ZLhWRiVJ6nIrCMu1lDcpnAPcVbhnRXVN+ex55FAHo9heLcqpB6cEe9dTpFz/pZB/jXFeYaNfmK4XngDkeo/wAa7TQ7o/bl9+5/nQB1d0f3cm3C856d68o+PT5+GWsjt+5/9HpXqkx3Bh6juK8m+O7Y+GusKc5Jh/8AR0dAHyhRRRQBu+CTjxPYn3f/ANAavoPSmDRL0/OvnfwiceIrQ+m7/wBANe+6M+Yo8cCgD0DTXyikkfhXT2BCwO3t3rktKY4QCumEgS2VFGTnB9qAC/nCQEE/fXGM9q46/l3xtGhHIwPb2rR8QagqzLhiQo2jP65rj9Ru2MrAEkeo45oAp3Uo3EbskdcHFU5JSVK5UORhcf4VFdMFJlODngE/570+1hkuG2QRPNck9V5x7UAPRMFeQHGC3oPX8fepZWDKC4w3QEnqP6V0Wk+FriX5tRkESDHyrz+ZrpbPw7Z28h8uBd2MFm5JoA8qOnahekLaW08qnqdu0fiTVu18FahI2yZkiy2TtyxJr2azsFTI2Dn25GPQ1bt9OQAnaMj17UAeYaX4ItYOZg8kinvwD+VasPg+zjcv5A3t1JFd+ttHH8pG4nv2FKLUGUxFSMY2v6+1AHFReHIU+7Gox0OKvf2BCefLXfjpjr712P2EY4XnI+UdqfHahQGlKovAyT+lAHJWfh1Y13hFyegI+7T10RT8569OetdmlvuztJwenFItnk9OvegChp8CxKgUY7c1vQqCAT07VQMSQnLttXOBn1rQhwFwORQBaRRwKtp09/5VVQ5x296sIM4IPH86AHjkdc04deOlIODjrQM57Y9qAHdvalPXn+dIKUdMCgBD+tNPuadimtwKAGkgn/61L3OfyqJjnn8qTdjIoAVxkjk4HYd6iYc/060pYYwajYgg0ARyHnpx37Yqo7ZOQePWrMp3DgZPvWfdNtYgjJPpQBSvkBDYOAw6k1xOpQssrvkcdRng12l2FkRlP159a5jU4C0m73zzQB594qsDLbyBF+ZhkHHQiuEtbd0nKyoxYcE+let3cYljKSHnqpHavPdfhW21B8EYbkKDjmgCqkyxSNnkggfL0Iq8pHmAqS2R0z0rBmuFUMVCkZOcnkcVDHqAA/dtls9Qe9AG5f5ADR4808FcYB+vv71QjuEQ8Aoyj7pPSlt78FPLm5yMgZ6GqN2okYNC2T39/wD69AG9b6gREGLAE9RjtXZ+DtS82UKSN0Y4yc5FeWR3QXGGG31963/Dupm1uVcEZzg+470Ae+wy+amSevBryf46n/i3usj0MX/o5K9F0i4ErBVztddw5rzf47N/xQOsDH8UX/o5KAPlqiiigDX8KHHiC0Pu3/oJr3XRn+ROegrwfwyca5an3b/0E17bojKUTIyMcj1oA9L0JtxQ9cDNbuoT+XaFtwyBgc+tc94dJ8kspUD7p4OfwqbxLd+XGIsnjnI7UAc/4hvAWReo2muUvLoEgKwL55I9ava7c7kV0J5O0Y+8a0vCmgGMrd3aBpP4UPIX/wCvQAuh+H5dQVZLsbExwnfH9K7rTNKhs0EcUSxx9MKOvvViziEacKWAGSF6n6VrW8KvhkI2thsgfeFACRw7UVTx9aswwhR82SexApkU0LXptfmaReuOinrWokPI4oAbBGBnOMn17VYVMZHYdzT4o8Hlh6fjVmJAePyyaAKjWkZDr5XMgOc9CenNSwRp1K4bGBx2qwgSSJipV1IIORwQMg5/WpbUpJFHJH8yOoKnBGR2680ANWLOM/lT2jU8EA/UfrUuML93npgUpXk7sEDoPSgCILuI4G31z1poXPUEHnvVgjPJ6dKXbzQBVaHcOQD655zUkaZ68ip9nFAQjHHGOaABBtzjg+9WF4AGc47k81Go5+lSjrkUALnBxinD86QUv4HNAC+9Ln0pPxwOvNKOmRigBDj86idc9alzikJ56UAVz19c9MUwqxAwD68VZbBGCOvb1pCTj2NAFZoyBycAfjQsSnqxIqxyOoGaZzjLEAevtQBEbaNjk89+tMe0hb7yZ/GrCg5LHAz0HpRgAHofrQBnPptocfuunuarTaRYOTm2U/Uk/wBa2GXnkEn+dNZMgkcUAYB0exQgrZw5B4ytZuraHp8mWaxgZhyD5Y4NdW6k9eT0qGeJSmMDNAHll14c0uaRt9lEN3/TMAVi3XgrRZCxFqiv6qSK9LubIB328Cs24smOXA+tAHj2p/D7JL2NxIMnoecVhaj4d1LTYy0kXmJjlk7Ad8da9xNowbdjA9D0qO4hWVCsqg574oA+bbnCkvGMr/Fjp9al02dpLmJg2cEAe1eo+LPBkF2jzWiCK5I4YDr9a8wi0+fTNUW3uIyjA8elAHtnhK+MnlDOTG2PwNc18e+PBGrDJ5MR/wDIqUeC7sx6xHC5xvBXH8qT47nzPh5qEn+3Gv8A5FSgD5cooooA0vDxxrNsfc/+gmvZdCl/dqQcivF9DONUgPuf5GvXdBfdHgjnGeaAPVtAYiCFORuXf+Oaw/FF+G1O9UE4RgOvQDitjRQubcgkbQPx46V5zqN9JLrVwFIZppGULnuTxQB0vhnTjqlyZ5FBjiPyA9zXodnaxhAqKuxRgewHasnwtZfZbGKIKTtGWIxyf0rqrdEjxtXGT2U0AS2kJUAdMetaEafK+GK8HBAzioIgu/GV9cE81dh4PGce9AEOm232dJ2lBYs+8MwG7PfnvyTWtEoz71V2q/lhyCynII4Gf89qvoFwCCDxjg54oAWEKxAxh8dMfyqXy8PuH3T8p4oQqGVc8nkD1qdAv3Tn+dAD1XPOMe1PA5OaRRz708DAxigBAMdOQKXbgnjqaXHp/OnYwenFACBcgdPrQAOemfSnLg5AzQB3PGP0oAFBzRjp/Klxz2x2zSj1/H6UAJt9+fapBz6VHGiooRFwo6DtUgGeTn6mgBR1PIwPSl+gpBx1I/Cl+hoAOMY6+oNKPfFICO3b0paAF7YpmOT2+lO5/wAikzknnpQAgGP/AK9IMsoLKVPoSDj8RSsQAR1+vemFjjPWgByqAXwWOTnBPA+lIyDOdufTnpSKxLELjH1qQcev0oAYVwO2aY/HU9KlI45OaYRlfegBhyPp9KafvH1p3PakyoYLuUNg4GaAIXDNIoAdVHzF1YYJ5G0jqRzn8uaZKBtPGRjGasHI64qJ/mTjOOnSgDKkiA4A+UDAqq0JYnIP41qyLtBLAn6daikXj0IFAGLPCrjBGPYcYrKmgMb7hnA710UqjeRzn6VRnjyCDyKAMN4g/Xn271yPi7wzHqVq8kSgXEeWRh612s0flNlRgd+KYYw6EHOOmaAPBdGvWtNWjlmJVo2AbPYg966X4zsH+G2r8E/6hwT/ANdU/wAay/iVpTaXqv2qNQIrg4OP71Xfi4/mfCy7kAPz29sTn/rpHQB8z0UUUAXNIONRh+p/ka9V8PSfKvJ9DXk1jIsN1G7nCr1P4V2+k+ItOt1Aludvf7jH+lAHvGmyhIgx4AQY/KvPdCtWvPE4YDcY3LDHr2/rVq1+InhtLRFfUiH2gEeRL/8AE1B4V8beFNPmnnutUCySMcf6PKePXhaAPbNLj2RIBj1JxWxGOcj6c15fa/FnwXGBu1oA/wDXrP8A/EVfi+MPgdf+Y7j/ALdJ/wD4igD0tFIX5Aue2RxVmCNCdyqATxnvivM0+MngQYZtfIPTi0n/AD/1dTp8Z/AKgD+3hjPIFncD/wBp0AeoRYwAzOe5BORVpA20dz2BHH515cnxr+HoIJ1/n1Flcf8AxurEfxw+HYPPiE4HpZXH/wAboA9Py3JVY8++akRiTggE9evSvMF+Ofw7CADxDnAxzY3H/wAbqQfHT4c4wfEXB6j7Dc//ABugD1JW4p4IOK8tX46/Dgf8zFj/ALcrn/43Sr8d/hz1/wCEj69f9Buf/jdAHqgxjHWlAB5wK8sHx4+HGP8AkYvzsbn/AON07/hfPw3/AOhjP/gDc/8AxugD1E+oJ47Cg9MivLv+F8/Dft4jx/243P8A8bpsXx6+HDJufxAY25BX7Fcn15/1f+c/hQB6ljPelwQDzzXl/wDwvr4b5/5GPp/043P/AMbpf+F8/DYAf8VH/wCSNz/8boA9QViMbsA/Wn5zzjmvLB8evhtnP/CRken+g3P/AMbp3/C+/htj/kYx/wCANz/8boA9Txn396d0PSvLB8fPhtnnxJ/5I3P/AMbpR8fPhr/0Mn/kjc//ABugD1LnHH60jAl0bceM5AJwfqO9eX/8L9+Gv/Qyf+SFz/8AG6P+F+/DXP8AyMn/AJIXP/xugD1Ln1xQ3XmvLf8Ahfvw1wf+Kk/8kbn/AON0x/j58N8HHiQ5P/Tjc/8AxugD1I845oIH4+prytfj38N8c+JP/JG5/wDjdOHx8+G3/Qyf+SNz/wDG6APTwMHNSfQYNeXf8L8+GvGfEmfX/Qbn/wCN0D4+fDUf8zJ/5I3P/wAboA9RA444NNIODgYavMD8fPhr/wBDJx/143P/AMbpv/C/PhtjnxHz3xY3P/xugD02RRICjYxxkA/lSnDHI/OvLJfjv8NSHK+IVDkdRYXIJOOMny+aVfj18OMAt4jG7HJFjc9f+/dAHqPrUbjBztya8x/4Xz8N/wDoYiP+3G5/+N0n/C+fhx1/4SM5H/Tjc/8AxugD0pxznoarSryB09PevO5Pjv8ADg9PEWff7Dc//G6rT/HL4duQB4hHHf7Dccf+Q6APQpMMDg5qpIvBBHNcE/xu+HjD/kP8/wDXlcf/ABuqh+NXgPB/4qLfx3srjP57P6UAdxcxgsRVKTKk5OSK4uT4z+BWB/4nuD/16XHP/jlULn4veCXI2a4SB/06TjP/AI5QBueNtLi1jRpInI3qNyt6GuD+LCtF8KJ0Y5ZYLdD9RKlar/FfwVIrK+sZUjBBtZjn/wAcriPif468Oa14PvtP0rUvPuJBGETyJFziRWPLKB0BoA8MooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33107=[""].join("\n");
var outline_f32_21_33107=null;
var title_f32_21_33108="Riluzole: Patient drug information";
var content_f32_21_33108=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Riluzole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     see \"Riluzole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rilutek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Riluzole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Riluzole;",
"     </li>",
"     <li>",
"      Rilutek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat amyotrophic lateral sclerosis (ALS).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to riluzole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12109 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-69ABC6F150-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33108=[""].join("\n");
var outline_f32_21_33108=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218370\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218371\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030721\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030720\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030725\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030726\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030728\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030723\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030724\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030729\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030730\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=related_link\">",
"      Riluzole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_21_33109="Citric acid bladder mixture: Drug information";
var content_f32_21_33109=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Citric acid bladder mixture: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/44/708?source=see_link\">",
"    see \"Citric acid bladder mixture: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Renacidin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Genitourinary Irrigant;",
"     </li>",
"     <li>",
"      Urinary Tract Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dissolution or prevention of calcifications:",
"     </b>",
"     Irrigation (indwelling urethral catheters): 30-60 mL 2-3 times/day by means of a rubber syringe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Renal calculi:",
"     </b>",
"     Irrigation: Infuse NS at 60 mL/hour and increase until pain, elevated pressure, or maximum flow rate of 120 mL/hour is reached. Begin flow of solution at maximum rate achieved with NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder calculi:",
"     </b>",
"     30 mL instilled through urinary catheter; clamp for 30-60 minutes, then release and drain; repeat 4-6 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F152231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, irrigation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renacidin&reg;: Citric acid 6.602 g, magnesium carbonate 3.177 g, glucono-delta-lactone 0.198 g per 100 mL (500 mL) [contains benzoic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue irrigation immediately if pain or fever occurs. Maintain patency of irrigating catheter; discontinue if obstructed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of formation of calcifications of indwelling urinary tract catheters; treatment of renal and bladder calculi of the apatite or struvite type",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F152246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Renacidin&reg; may be confused with Remicade&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (20% to 40%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urothelial ulceration with or without edema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Transient flank pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypermagnesemia, hyperphosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection, dysuria, hematuria, bladder irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Septicemia, ileus, vomiting, thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; urinary tract infection; treatment of calcium oxalate, uric acid, or cysteine calculi",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypermagnesemia: Severe hypermagnesemia has occurred; monitor magnesium levels closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with impaired renal function.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F152225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is excreted in human milk; it is not known if the combination of ingredients used by irrigation are excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F152217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum creatinine, serum phosphate, serum magnesium; urine cultures",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium from the irrigating solution is exchanged for calcium in the stone matrix. The magnesium stones are soluble and are able to dissolve in the acidic pH of the solution.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8877 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33109=[""].join("\n");
var outline_f32_21_33109=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152229\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152241\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152230\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152231\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152208\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152221\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152220\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152246\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152239\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152223\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152211\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299051\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219334\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152216\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152224\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152233\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152225\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152217\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152210\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/44/708?source=related_link\">",
"      Citric acid bladder mixture: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_21_33110="Cholesterol emboli in transit";
var content_f32_21_33110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Emboli in transit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiogram of the descending thoracic aorta in a patient who later died from cholesterol crystal embolization syndrome, with intestinal infarction and renal failure. Note the massive atherosclerotic plaque. The pictures on the right (1A, 2A, 3A) were taken one or two seconds after their respective pictures on the left. The arrows point to small particles of embolic material moving in transit in the aortic lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Freedberg, RS, Tunick, PA, Kronzon, I. Emboli in Transit: The Missing Link. J Am Soc Echocardiogr 1998, 11:826. Copyright &copy; 1998 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33110=[""].join("\n");
var outline_f32_21_33110=null;
var title_f32_21_33111="Vascular invasion";
var content_f32_21_33111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55403&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Vascular invasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascular invasion by urothelial carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33111=[""].join("\n");
var outline_f32_21_33111=null;
var title_f32_21_33112="12-lead ECG WPW concertina effect";
var content_f32_21_33112=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing concertina effect in Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG and rhythm strip during sinus rhythm shows a short PR interval and QRS complex which is aberrated and has a delta wave. After the fifth complex on the rhythm strip, there is a sinus pause after which the QRS compex is still aberrated but the PR interval is somewhat longer. Subsequently, the PR interval becomes progressively shorter. This variability in the PR interval during sinus rhythm is known as the \"concertina effect\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33112=[""].join("\n");
var outline_f32_21_33112=null;
var title_f32_21_33113="Prevention of osteoporosis";
var content_f32_21_33113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     E Michael Lewiecki, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33113/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/21/33113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis or low bone mass (osteopenia) occurs in about 44 million American men and women, accounting for 55 percent of the population age 50 and over [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/1\">",
"     1",
"    </a>",
"    ]. Osteoporosis has been defined as \"a skeletal disease characterized by compromised bone strength predisposing a person to an increased risk of fracture\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of osteoporosis using nonpharmacological and pharmacological therapies will be discussed here. The prevention of glucocorticoid-induced osteoporosis and the treatment of established osteoporosis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone strength primarily reflects the integration of bone density and other properties of bone that are collectively called \"bone quality\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/2\">",
"     2",
"    </a>",
"    ]. In the absence of a fragility fracture, bone mineral density (BMD) by dual-energy x-ray absorptiometry (DXA) is used to diagnose osteoporosis according to the classification of the World Health Organization (WHO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BMD that is 2.5 standard deviations (SD) or more below the mean BMD of a young-adult reference population, which is a T-score of -2.5 or less, qualifies for a diagnosis of osteoporosis, provided that other causes of low BMD have been ruled out. As BMD decreases, fracture risk increases as a continuum, with no \"fracture threshold.\" In one analysis, for every one SD decrease in BMD at the hip, there is a 2.6-fold increase in the risk of hip fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Why prevention?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of osteoporosis or low BMD is preferable to treatment because bone microarchitectural changes associated with bone loss are largely irreversible. Treatment may stabilize or increase BMD and reduce the risk of fracture, but is unlikely to fully restore bone quality and bone strength. BMD in adults is determined by peak bone mass (PBM) and the rate of bone loss. The prevention of osteoporosis or low BMD is directed to maximizing peak bone mass and minimizing the rate of bone loss, with the ultimate goals of maintaining bone strength and preventing fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAXIMIZING PEAK BONE MASS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PBM is the maximum bone mass achieved in life. The time of PBM is not known with certainty, but probably occurs in the third decade of life in most individuals, with differences in timing due to genetic and hormonal variables, the skeletal site measured, and the method of BMD measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of identical twins have demonstrated that 60 to 70 percent of the variability in the magnitude of PBM is genetically determined, as expressed by phenotypes such as ethnicity, sex, and body size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/6\">",
"     6",
"    </a>",
"    ]. The remaining 30 to 40 percent of variability is related to environmental factors such as diet, exercise, habits, diseases, and medications. A study of 668 healthy premenopausal women showed that low body weight, menarche at age 15 years or later, and physical inactivity as an adolescent were independent predictors of low bone mass by both DXA and quantitative ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies in premenopausal women have identified cigarette smoking, low body mass index (BMI), and Caucasian or Asian ethnicity as risk factors associated with low BMD. Cigarette smoking has also been associated with decreased BMD and reduced cortical thickness in young men 18 to 20 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with congenital disorders, such as osteogenesis imperfecta and cystic fibrosis, are now being more successfully managed in childhood, so that more survive and reach adulthood with low PBM.",
"   </p>",
"   <p>",
"    The statement of Professor Charles E. Dent that \"senile osteoporosis is a pediatric disease\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/9\">",
"     9",
"    </a>",
"    ] illustrates the importance of achieving the maximum potential PBM, thereby attenuating the effects of bone loss later in life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonpharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions to optimize PBM and skeletal health should be directed toward a healthy lifestyle during the bone-forming years. These can be divided into categories of nutrition, physical activity, and other lifestyle factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Good nutrition from infancy through adolescence, with particular attention to adequate daily intake of calcium and vitamin D, is a key component in the attainment of maximum PBM as highlighted by a number of studies (",
"    <a class=\"graphic graphic_table graphicRef71669 \" href=\"mobipreview.htm?26/10/26797\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A three-year study of identical twins, ages 6 to 14, showed a significant increase in BMD in those who took calcium supplements (1000",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      compared with those who did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/10\">",
"       10",
"      </a>",
"      ]. The benefit of vitamin D independently of calcium intake has been more difficult to demonstrate in clinical trials.",
"     </li>",
"     <li>",
"      A study of 106 healthy prepubertal girls showed that those receiving vitamin D supplementation in infancy had higher bone mass at the femoral neck, but not the lumbar spine, compared with those who had no supplementation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There have been some studies showing that high consumption of carbonated soft drinks may impair bone acquisition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/12\">",
"       12",
"      </a>",
"      ] and increase fracture risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/13\">",
"       13",
"      </a>",
"      ] in girls. However, other studies have shown that this effect is largely a matter of displacement of more nutritious beverages, and that it may be reversed by taking the recommended daily intake of calcium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anorexia nervosa, an increasingly common eating disorder in female adolescents, is associated with reduced BMD and increased fracture risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=see_link&amp;anchor=H27332237#H27332237\">",
"       \"Anorexia nervosa in adults and adolescents: Medical complications and their management\", section on 'Osteoporosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other nutritional disorders known to impair bone accretion in adolescence include inflammatory bowel disease, celiac disease, and cystic fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=see_link\">",
"       \"Metabolic bone disease in inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H21#H21\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Metabolic bone disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link&amp;anchor=H14#H14\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Musculoskeletal disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational, retrospective, and prospective randomized trials have demonstrated beneficial effects of exercise on bone accumulation during growth, with particular benefit from high impact exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. On the other hand, excessive exercise can be harmful to skeletal health when it is accompanied by poor nutrition and reduced body fat, as seen in adolescents and young adults with female athlete triad (disordered eating, amenorrhea, osteoporosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other lifestyle factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking and excess alcohol intake should be discouraged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In addition, administration of drugs that are known to be harmful to skeletal health, such as glucocorticoids and anticonvulsants, should be avoided or minimized in dose and duration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pharmacological therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for pharmacological therapy as a means to maximize PBM, except in very special circumstances. As an example, hormone replacement for deficiency states in children, such as growth hormone deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/25\">",
"     25",
"    </a>",
"    ], and pharmacological doses of vitamin D for some children on anticonvulsant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/26\">",
"     26",
"    </a>",
"    ] or with celiac disease may be necessary to optimize skeletal health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BONE LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss may begin soon after PBM is attained. Factors that influence the rate and magnitude of bone loss include hormone concentrations, age, body weight, BMI, calcium and vitamin D intake, physical activity, alcohol consumption, family history of osteoporosis, and cigarette smoking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link\">",
"     \"Pathogenesis of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;A typical rate of bone loss in early postmenopausal estrogen deficient women is probably about 0.5 to 1.5 percent per year, with a small percentage of women being \"rapid bone losers\" who may lose as much as 3 to 5 percent of bone mass per year. The rate of bone loss is highly dependent upon hormonal, environmental, and genetic factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=see_link\">",
"     \"Clinical manifestations and diagnosis of menopause\"",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a longitudinal study of 272 healthy pre- and perimenopausal women, no bone loss was observed in premenopausal women, while accelerated bone loss was observed in the two to three years prior to cessation of menstruation, with a significant correlation between the rate of bone loss and elevation of follicle stimulating hormone (FSH) and bone turnover markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another longitudinal study, perimenopausal women randomly assigned to lifestyle modification aimed at preventing weight gain or promoting weight loss had greater rates of hip bone loss than control women (who gained 2.6 kg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/28\">",
"       28",
"      </a>",
"      ]. Those who lost more weight (&gt;3 percent body weight) experienced greater decreases in hip BMD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low BMD in perimenopausal women is a risk factor for fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/29\">",
"     29",
"    </a>",
"    ]. Further study is needed to better define correlates with changes in BMD and fracture risk in women prior to menopause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Age-related bone loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-related bone loss in older women and men is about 0.5 to 1.0 percent per year. Reported rates of bone loss vary according to the type of study (cross-sectional versus longitudinal), skeletal site, skeletal compartment (trabecular versus cortical), type of measurement, ethnicity, sex, and other confounding factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link&amp;anchor=H341623#H341623\">",
"     \"Pathogenesis of osteoporosis\", section on 'Old age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a longitudinal study of 620 men and women age 20 to 89 showed a small bone loss (&lt;0.4 percent per year) at the hip and spine in premenopausal women, with a tripling of the bone loss rate in the early postmenopausal years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/33\">",
"     33",
"    </a>",
"    ]. In men under age 50 there was a slow rate of bone loss at the hip, but not the spine, that continued throughout life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MINIMIZING BONE LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stabilizing BMD or reducing the rate of bone loss is the primary objective in the prevention of osteoporosis once PBM has been attained. The Surgeon General's Report on Bone Health and Osteoporosis recommends a pyramid approach to the prevention and treatment of osteoporosis, with a foundation of lifestyle changes that include nutrition, physical activity, and fall prevention; a second tier of addressing drugs and diseases associated with bone loss or osteoporosis; and a third tier of pharmacological therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Calcium and vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium and vitamin D are necessary for normal skeletal homeostasis. Vitamin D enhances intestinal absorption of calcium and is important for mineralization of bone, as well as optimal muscle function and balance. Low concentrations of vitamin D are associated with impaired calcium absorption, a negative calcium balance, and a compensatory rise in parathyroid hormone, which results in excessive bone resorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Benefits of vitamin D repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While it is often difficult to distinguish effects of calcium from vitamin D in clinical trials, some meta-analyses have shown increases in BMD and a reduction in fracture risk in elderly patients supplemented with calcium and vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H2#H2\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Recommended Dietary Allowance (RDA) of elemental calcium for postmenopausal women is 1200 mg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/1,22,34\">",
"     1,22,34",
"    </a>",
"    ], which is much more than the average daily intake in this population (",
"    <a class=\"graphic graphic_table graphicRef71669 \" href=\"mobipreview.htm?26/10/26797\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Although the optimal intake (diet plus supplement) has not been clearly established in premenopausal women or in men, 1000 mg of calcium is generally suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/34\">",
"     34",
"    </a>",
"    ]. The RDA of vitamin D for children 1 to 18 years and adults through age 70 years is 600 international units (15 mcg) with the RDA increasing to 800 international units (20 mcg) after age 71 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/34\">",
"     34",
"    </a>",
"    ]. However, older persons confined indoors and other high risk groups may have low serum 25-hydroxyvitamin D concentrations at this intake level and may require higher intakes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Optimal intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest 800 international units of vitamin D daily and 1200 mg elemental calcium (total diet plus supplements, if needed) daily for most older individuals. In patients at very high risk for osteoporosis in whom there is a clinical suspicion that the usual doses are inadequate (malabsorption, decreasing bone mass), measurement of 25OHD concentrations may be necessary to ensure that supplementation is adequate, with the caveat that assay variability may be significant. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H6#H6\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Optimal intake'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Biochemical criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Optimal intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is a history of nephrolithiasis, additional evaluation is required before making supplementation recommendations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight-bearing exercise is associated with small but significant improvement in BMD in premenopausal and postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/38\">",
"     38",
"    </a>",
"    ] and in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/39\">",
"     39",
"    </a>",
"    ]. It may also improve muscle tone and reduce the risk of falls. The Surgeon General recommends a \"minimum of 30 minutes of physical activity (such as brisk walking) on most, if not all, days of the week\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other lifestyle factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have shown that cigarette smoking is associated with reduced BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/41\">",
"     41",
"    </a>",
"    ] and increased risk of fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/42\">",
"     42",
"    </a>",
"    ]. Every effort should be made to discourage initiation or continuation of cigarette smoking. Excess alcohol is detrimental to skeletal health for many reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/43\">",
"     43",
"    </a>",
"    ], although moderate alcohol drinking has been associated with higher bone mass in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Moderation in alcohol intake is appropriate, although patients should not be advised to initiate alcohol drinking to improve skeletal health. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of the risks and benefits of alcohol consumption\", section on 'Osteoporosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY TO MINIMIZE BONE LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the Food and Drug Administration (FDA) distinguishes between drugs approved for prevention of osteoporosis and those for treatment, and has published guidelines for the design of clinical trials to support an application for registration of new osteoporosis drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For prevention, the study population should consist of ambulatory outpatient women who are one to two years postmenopausal, age 45 or older, and do not have osteoporosis (defined by the US Food and Drug Administration as lumbar spine T-score -2.0 or less",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    one or more fragility fractures of the spine) or ovariectomized women with an elevated follicle stimulating hormone (FSH) level and low serum estradiol.",
"   </p>",
"   <p>",
"    Studies should be at least two years duration, randomized, double-blind, placebo-controlled with multiple dosing arms, and of sufficient sample size to evaluate safety and efficacy. Once a drug has been shown to reduce fracture risk, then demonstration of preservation or enhancement of BMD is a sufficient efficacy endpoint in a prevention trial.",
"   </p>",
"   <p>",
"    In contrast, studies to demonstrate efficacy in the treatment of osteoporosis are done in an older population (usually age 60 and older), at least five years postmenopausal, who have a lumbar spine T-score -2.0 or below",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    one or more fragility fractures of the spine. Treatment studies are done over at least three years and must show at least a trend (p&lt;0.2) in reduction in fracture risk.",
"   </p>",
"   <p>",
"    Drugs that are currently approved for the prevention of osteoporosis are estrogen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef64685 \" href=\"mobipreview.htm?14/62/15339\">",
"     table 2",
"    </a>",
"    ). The prevention drugs are reviewed below.",
"   </p>",
"   <p>",
"    For the majority of postmenopausal women, we suggest not using pharmacological therapy for prevention of osteoporosis. However, for postmenopausal women who are candidates for and desire pharmacological therapy for prevention of osteoporosis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    or an oral bisphosphonate are reasonable choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Women's Health Initiative (WHI) showed that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    (CEE) 0.625",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA) 2.5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    reduced the risk of hip, vertebral, and other fractures in healthy postmenopausal women (mean age 63 to 64 at beginning of study) not selected on the basis of low BMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, it was determined that in the WHI population, the risks of estrogen exceeded the benefits, even in women at high risk for fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/49\">",
"     49",
"    </a>",
"    ]. This topic is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Estrogen is not currently recommended as a first-line agent in the management of osteoporosis, and should be used for the prevention of postmenopausal osteoporosis only in women at significant risk who cannot take non-estrogen medications. Whether the results and conclusions of the WHI apply to younger postmenopausal women taking estrogen in other doses, formulations, or modes of administration is not known.",
"   </p>",
"   <p>",
"    Doses of estrogen lower than that used in the WHI have been shown to have skeletal benefits. The Women's HOPE study showed that doses of CEE as low as 0.3",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with or without MPA, increased BMD at the hip and spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/50\">",
"     50",
"    </a>",
"    ]. Low dose 17beta-estradiol therapy (0.25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    has also been shown to increase BMD, with minimal reported adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/51\">",
"     51",
"    </a>",
"    ]. If an estrogen is used for any reason, it should be taken in the lowest possible dose for the shortest period of time needed to achieve the goals of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications in this class of potent antiresorptive agents have been shown to increase BMD and reduce fracture risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Those currently available for the prevention of postmenopausal osteoporosis are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 35",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 35",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mg/month),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (5 mg intravenously [IV] once every two years).",
"   </p>",
"   <p>",
"    The approved prevention dose with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    is one-half the dose for treatment, while the prevention and treatment doses are the same for the others. For prevention versus treatment of osteoporosis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , the interval between doses is longer (every two years versus once yearly).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     Ibandronate",
"    </a>",
"    is also approved for 2.5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but this dosing form is not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its efficacy in the treatment of osteoporosis in postmenopausal women,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    is useful for the prevention of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/55-59\">",
"     55-59",
"    </a>",
"    ]. The approved prevention dose with alendronate is one-half the dose for treatment (5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or 35",
"    <span class=\"nowrap\">",
"     mg/week).",
"    </span>",
"   </p>",
"   <p>",
"    As",
"    an example, in a double-blind, randomized trial of 447 women who had been menopausal for 6 to 36 months,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    for three years at 5, 10, and 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increased bone mineral density at the lumbar spine, femoral neck, and trochanter by 1 to 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/55\">",
"     55",
"    </a>",
"    ]. In comparison, those receiving placebo lost 2 to 4 percent at these sites. The protective effect of alendronate disappeared relatively rapidly after cessation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second randomized study found similar efficacy (3.5 percent increase in bone mineral density at the lumbar spine and 1.9 percent increase at the hip) with the 5 mg dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    administered to postmenopausal women under the age of 60 years for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/57\">",
"     57",
"    </a>",
"    ]. In a follow-up study of this cohort for four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/58\">",
"     58",
"    </a>",
"    ] and six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/59\">",
"     59",
"    </a>",
"    ], the positive effects of continued therapy on bone density were maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/58\">",
"     58",
"    </a>",
"    ]. This dose was as, or perhaps slightly less, beneficial than estrogen-progestin therapy. Women receiving alendronate during years one and two who then received placebo in years three and four had the expected fall in bone density.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    increases BMD in postmenopausal women without osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/55,59\">",
"     55,59",
"    </a>",
"    ], there is no consensus on when to initiate therapy in postmenopausal women with osteopenia (femoral neck T-scores between -1.5 and -2.4). One group of investigators calculated that treating these women would not be cost-effective from a societal standpoint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/60\">",
"     60",
"    </a>",
"    ]. However, this does not imply that an individual postmenopausal woman with osteopenia would not derive fracture benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is also effective for prevention of bone loss and fracture in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/53,61,62\">",
"     53,61,62",
"    </a>",
"    ]. As an example, in a two-year trial of risedronate (5 mg daily) versus placebo in 111 postmenopausal women with normal BMD, there was a mean increase in BMD of the lumbar spine (1.4 percent) in the risedronate group versus a decline (4.3 percent) in the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ibandronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    has been shown to improve BMD in postmenopausal women without osteoporosis, as illustrated by the findings of a 24-month trial of ibandronate (2.5 mg daily) versus placebo in 653 postmenopausal women without osteoporosis (baseline T-score better than -2.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/63\">",
"     63",
"    </a>",
"    ]. Daily oral ibandronate increased BMD at the lumbar spine and hip (3.1 and 1.8 percent, respectively, compared with placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a two-year trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (5 mg IV once at baseline or yearly for two years) versus placebo in 581 postmenopausal women with osteopenia, patients randomly assigned to a single zoledronic acid infusion had significant increases in LS and total hip BMD (approximately 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/64\">",
"     64",
"    </a>",
"    ]. The study was not powered to detect differences in fracture risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the bisphosphonates that are taken orally must be administered with particular attention to proper procedures. They should be taken with a glass of plain water on an empty stomach following an overnight fast, with no food, drink, medications, or supplements to follow for at least one-half hour (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ) or one hour (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ). Absorption is very poor, typically less than 1 percent of the oral dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/65\">",
"     65",
"    </a>",
"    ]. Bioavailability may be seriously impaired by ingestion with liquids other than plain water, such as mineral water, coffee, or juice, or by retained gastric contents, as with insufficient fasting time or gastroparesis, or by eating or drinking too soon after taking the bisphosphonate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H2#H2\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'General principles'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The patient should also remain upright after taking the medication, until the fast is broken. Reclining soon after taking an oral bisphosphonate may result in esophageal irritation in patients with gastro-esophageal reflux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In clinical trials, adverse gastrointestinal (GI) events were no different in those taking active drug compared to placebo, although the experience in clinical practice is that oral bisphosphonates may be associated with a small increase in risk of GI toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/66\">",
"     66",
"    </a>",
"    ]. The trend with bisphosphonate therapy is toward less frequent dosing and parenteral dosing, which may improve poor adherence to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/67\">",
"     67",
"    </a>",
"    ], which is a well-documented problem in the management of osteoporosis and many other chronic asymptomatic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common adverse effect of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is an acute-phase reaction (fever, flu-like symptoms, headache, arthralgia, and myalgia). There have been isolated case reports of renal insufficiency after zoledronic acid administration, particularly in patients with multiple myeloma but also rarely in those treated for osteoporosis and those receiving concurrent diuretic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H6#H6\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'IV regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H2#H2\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Proteinuria and renal insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Selective estrogen receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is the only SERM currently approved in the United States for the prevention of postmenopausal osteoporosis. It has been shown to increase BMD and reduce the risk of vertebral fractures but not nonvertebral fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/70\">",
"     70",
"    </a>",
"    ]. Important nonskeletal considerations with raloxifene include reduction in breast cancer risk, increased risk of thromboembolic events, and hot flashes. There is no apparent effect on heart disease or the endometrium.",
"   </p>",
"   <p>",
"    Other SERMs in development for the management of osteoporosis include lasofoxifene and bazedoxifene.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=see_link\">",
"     \"Selective estrogen receptor modulators for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FRACTURE PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive nonpharmacological therapy in order to preserve BMD, bone microarchitecture, and bone strength.",
"   </p>",
"   <p>",
"    Although drugs approved for the prevention of osteoporosis do not have to show reduction in fracture risk in early postmenopausal women without osteoporosis, it must be recognized that most fractures occur in women who do not have osteoporosis by T-score criteria. Patients with osteoporosis are at the highest risk of fracture, but there are more fractures in patients with low bone mass or osteopenia (T-score between -1.0 and -2.5) because there are so many more patients in this category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33113/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H2#H2\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Assessment of fracture risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since pharmacological therapy has significant costs and associated risks, only some patients are candidates for preventive drugs. Patients with the highest risk of fracture are the ones most likely to benefit from drug therapy; therefore, selection of patients based upon fracture risk, as determined by a combination of BMD and clinical risk factors, is desirable.",
"   </p>",
"   <p>",
"    Based upon the US-adapted World Health Organization algorithm (FRAX), the National Osteoporosis Foundation recommends treatment of patients with low bone mass (T-score between -1.0 and -2.5 at the femoral neck or lumbar spine) if there is an estimated 10-year probability of hip fracture of &ge;3 percent or of major osteoporotic fracture &ge;20 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical application of fracture risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=see_link\">",
"       \"Patient information: Medicines for osteoporosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a preventable disease, not an inevitable consequence of aging. The management of skeletal health should be directed toward maximizing peak bone mass and minimizing bone loss that occurs with aging and declining sex hormone levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Nonpharmacological",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive nonpharmacological therapy in order to preserve BMD, bone microarchitecture, and bone strength.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For maximizing peak bone mass during the bone-forming years, we suggest healthy lifestyle measures, including adequate calcium intake, adequate vitamin D intake, physical activity (although not excessive), and avoidance of cigarette smoking and alcohol.",
"     </li>",
"     <li>",
"      For prevention of subsequent bone loss in adults, we suggest similar healthy lifestyle measures that include regular weight-bearing exercise, avoidance of cigarette smoking, and limitation of alcohol to an average of no more than two drinks daily.",
"     </li>",
"     <li>",
"      We suggest calcium supplements in individuals with inadequate dietary calcium intake (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Recommended calcium intake for postmenopausal women is about 1200 mg daily (total diet plus supplement) (",
"      <a class=\"graphic graphic_table graphicRef71669 \" href=\"mobipreview.htm?26/10/26797\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Calcium and vitamin D'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest vitamin D supplementation if dietary intake is inadequate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Recommended vitamin D intake is 600 international units daily in younger individuals and at least 800 international units daily in older adults. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Calcium and vitamin D'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Pharmacological",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional risk factors for bone loss and fractures should be identified and treated. Since pharmacological therapy has significant costs and associated risks, only some patients are candidates for preventive drugs. Patients with osteopenia (T-score between -1.0 and -2.5) should be considered for pharmacological intervention based upon fracture risk, as determined by a combination of BMD and clinical risk factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors that are best validated include advanced age, prior fragility fracture, parental history of hip fracture, glucocorticoid use, excess alcohol intake, rheumatoid arthritis, and current cigarette smoking. Patients with the highest probability of fracture are most likely to benefit from drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the majority of postmenopausal women, we suggest not using pharmacological therapy for prevention of osteoporosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pharmacologic therapy to minimize bone loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women who are candidates for and desire pharmacological therapy for prevention of osteoporosis, we suggest bisphosphonates or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      as first-line choices (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pharmacologic therapy to minimize bone loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are nonskeletal considerations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    that may play an important role in the selection of patients for therapy: a reduction in breast cancer risk, but an increase in thromboembolic events and hot flashes, and no apparent effect on heart disease or the endometrium. The dose for raloxifene is 60 mg daily.",
"   </p>",
"   <p>",
"    The bisphosphonate dose for prevention is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    5 mg daily or 35 mg once weekly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    5 mg daily or 35 mg once weekly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    150 mg once monthly, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    5 mg IV once every two years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis, 2008 file://www.nof.org/sites/default/files/pdfs/NOF_Clinicians_Guide2008.pdf (Accessed on June 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/2\">",
"      NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Study Group. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis (Technical Report Series), World Health Organization, Geneva, Switzerland 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/4\">",
"      Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/5\">",
"      Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int 2000; 11:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/6\">",
"      Pocock NA, Eisman JA, Hopper JL, et al. Genetic determinants of bone mass in adults. A twin study. J Clin Invest 1987; 80:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/7\">",
"      Hawker GA, Jamal SA, Ridout R, Chase C. A clinical prediction rule to identify premenopausal women with low bone mass. Osteoporos Int 2002; 13:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/8\">",
"      Lorentzon M, Mellstr&ouml;m D, Haug E, Ohlsson C. Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007; 92:497.",
"     </a>",
"    </li>",
"    <li>",
"     Dent, CE. Keynote address: Problems in metabolic bone disease. Proceedings of the International Symposium on Clinical Aspects of Metabolic Bone Disease 1973; 1-7.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/10\">",
"      Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992; 327:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/11\">",
"      Zamora SA, Rizzoli R, Belli DC, et al. Vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls. J Clin Endocrinol Metab 1999; 84:4541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/12\">",
"      Whiting SJ, Vatanparast H, Baxter-Jones A, et al. Factors that affect bone mineral accrual in the adolescent growth spurt. J Nutr 2004; 134:696S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/13\">",
"      Wyshak G. Teenaged girls, carbonated beverage consumption, and bone fractures. Arch Pediatr Adolesc Med 2000; 154:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/14\">",
"      McGartland C, Robson PJ, Murray L, et al. Carbonated soft drink consumption and bone mineral density in adolescence: the Northern Ireland Young Hearts project. J Bone Miner Res 2003; 18:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/15\">",
"      Fitzpatrick L, Heaney RP. Got soda? J Bone Miner Res 2003; 18:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/16\">",
"      Soyka LA, Grinspoon S, Levitsky LL, et al. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 1999; 84:4489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/17\">",
"      Herzog W, Minne H, Deter C, et al. Outcome of bone mineral density in anorexia nervosa patients 11.7 years after first admission. J Bone Miner Res 1993; 8:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/18\">",
"      Gordon CM. Normal bone accretion and effects of nutritional disorders in childhood. J Womens Health (Larchmt) 2003; 12:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/19\">",
"      Lima F, De Falco V, Baima J, et al. Effect of impact load and active load on bone metabolism and body composition of adolescent athletes. Med Sci Sports Exerc 2001; 33:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/20\">",
"      Petit MA, McKay HA, MacKelvie KJ, et al. A randomized school-based jumping intervention confers site and maturity-specific benefits on bone structural properties in girls: a hip structural analysis study. J Bone Miner Res 2002; 17:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/21\">",
"      Golden NH. A review of the female athlete triad (amenorrhea, osteoporosis and disordered eating). Int J Adolesc Med Health 2002; 14:9.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General, 2004. file://www.surgeongeneral.gov/library/bonehealth/content.html (Accessed on October 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/23\">",
"      Elg&aacute;n C, Samsioe G, Dykes AK. Influence of smoking and oral contraceptives on bone mineral density and bone remodeling in young women: a 2-year study. Contraception 2003; 67:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/24\">",
"      Elg&aacute;n C, Dykes AK, Samsioe G. Bone mineral density changes in young women: a two year study. Gynecol Endocrinol 2004; 19:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/25\">",
"      Bex M, Bouillon R. Growth hormone and bone health. Horm Res 2003; 60 Suppl 3:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/26\">",
"      Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 1994; 16:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/27\">",
"      Chapurlat RD, Garnero P, Sornay-Rendu E, et al. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000; 11:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/28\">",
"      Park HA, Lee JS, Kuller LH, Cauley JA. Effects of weight control during the menopausal transition on bone mineral density. J Clin Endocrinol Metab 2007; 92:3809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/29\">",
"      Kr&ouml;ger H, Huopio J, Honkanen R, et al. Prediction of fracture risk using axial bone mineral density in a perimenopausal population: a prospective study. J Bone Miner Res 1995; 10:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/30\">",
"      Melton LJ 3rd, Khosla S, Atkinson EJ, et al. Cross-sectional versus longitudinal evaluation of bone loss in men and women. Osteoporos Int 2000; 11:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/31\">",
"      Cauley JA, Lui LY, Stone KL, et al. Longitudinal study of changes in hip bone mineral density in Caucasian and African-American women. J Am Geriatr Soc 2005; 53:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/32\">",
"      Hochberg MC, Lethbridge-Cejku M, Tobin JD. Bone mineral density and osteoarthritis: data from the Baltimore Longitudinal Study of Aging. Osteoarthritis Cartilage 2004; 12 Suppl A:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/33\">",
"      Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 2002; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Report at a Glance, Report Brief: Dietary Reference Intakes for Calcium and Vitamin D, released 11/30/2010. file://www.iom.edu/Reports/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx (Accessed on December 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/35\">",
"      Looker AC, Loria CM, Carroll MD, et al. Calcium intakes of Mexican Americans, Cubans, Puerto Ricans, non-Hispanic whites, and non-Hispanic blacks in the United States. J Am Diet Assoc 1993; 93:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/36\">",
"      Looker AC, Harris TB, Madans JH, Sempos CT. Dietary calcium and hip fracture risk: the NHANES I Epidemiologic Follow-Up Study. Osteoporos Int 1993; 3:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/37\">",
"      Looker AC. Interaction of science, consumer practices and policy: calcium and bone health as a case study. J Nutr 2003; 133:1987S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/38\">",
"      Wolff I, van Croonenborg JJ, Kemper HC, et al. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int 1999; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/39\">",
"      Kelley GA, Kelley KS, Tran ZV. Exercise and bone mineral density in men: a meta-analysis. J Appl Physiol 2000; 88:1730.",
"     </a>",
"    </li>",
"    <li>",
"     United States, Public Health Service, Office of the Surgeon General. Physical activity and health: a report of the Surgeon General. U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Ga 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/41\">",
"      Ward KD, Klesges RC. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int 2001; 68:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/42\">",
"      Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/43\">",
"      Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005; 16:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/44\">",
"      Sampson HW. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health 2002; 26:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/45\">",
"      Felson DT, Zhang Y, Hannan MT, et al. Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995; 142:485.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Division of Metabolic and Endocrine Drug Products. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis, April 1994. file://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM131206.pdf (Accessed on November 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/47\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/48\">",
"      Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/49\">",
"      Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/50\">",
"      Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002; 287:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/51\">",
"      Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/52\">",
"      Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/53\">",
"      Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/54\">",
"      Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/55\">",
"      McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med 1998; 128:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/56\">",
"      Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000; 85:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/57\">",
"      Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 1998; 338:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/58\">",
"      Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/59\">",
"      McClung MR, Wasnich RD, Hosking DJ, et al. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004; 89:4879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/60\">",
"      Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 2005; 142:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/61\">",
"      Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/62\">",
"      Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000; 85:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/63\">",
"      McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res 2004; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/64\">",
"      Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis. Med Lett Drugs Ther 2009; 51:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/65\">",
"      Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/66\">",
"      Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord 2002; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/67\">",
"      Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002; 24:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/68\">",
"      Solomon DH, Brookhart MA, Gandhi TK, et al. Adherence with osteoporosis practice guidelines: a multilevel analysis of patient, physician, and practice setting characteristics. Am J Med 2004; 117:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/69\">",
"      Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33113/abstract/70\">",
"      Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2054 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-218.28.111.102-5CC63B1F68-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33113=[""].join("\n");
var outline_f32_21_33113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Why prevention?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAXIMIZING PEAK BONE MASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Physical activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other lifestyle factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pharmacological therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BONE LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Age-related bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MINIMIZING BONE LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other lifestyle factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PHARMACOLOGIC THERAPY TO MINIMIZE BONE LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Alendronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Risedronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ibandronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FRACTURE PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Nonpharmacological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Pharmacological",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2054\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2054|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/10/26797\" title=\"table 1\">",
"      IOM DRIs for calcium and vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/62/15339\" title=\"table 2\">",
"      Drugs prevention osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38890?source=related_link\">",
"      Anorexia nervosa in adults and adolescents: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/45/44761?source=related_link\">",
"      Clinical manifestations and diagnosis of menopause",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/41/6803?source=related_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/32/41481?source=related_link\">",
"      Selective estrogen receptor modulators for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_21_33114="Management of normal labor and delivery";
var content_f32_21_33114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of normal labor and delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Edmund F Funai, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/21/33114/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/21/33114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Labor is the physiological process by which a fetus is expelled from the uterus to the outside world. Determining whether a woman is in labor is sometimes difficult as painful uterine contractions alone are not sufficient to establish a diagnosis of labor. Typically, the diagnosis is reserved for uterine contractions which result in cervical dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effacement. Bloody show (a small amount of blood with mucus discharge [ie, mucus plug] from the cervix) may precede the onset of labor by as much as 72 hours. Occasionally, fetal membranes rupture with egress of amniotic fluid prior to the onset of labor.",
"   </p>",
"   <p>",
"    This topic will present a paradigm for intrapartum management of women in labor. Many of the options for evaluating and managing women during labor have not been studied in clinical trials or the data from clinical trials is insufficient for evidence-based decision-making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/1\">",
"     1",
"    </a>",
"    ]; thus, many of our recommendations are based upon clinical experience.",
"   </p>",
"   <p>",
"    Management of complicated deliveries is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13448?source=see_link\">",
"     \"Overview of breech presentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38326?source=see_link\">",
"     \"Face and brow presentations in labor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3729454\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) defines normal birth as: &ldquo;spontaneous in onset, low-risk at the start of labor and remaining so throughout labor and delivery. The infant is born spontaneously in the vertex position between 37 and 42 completed weeks of pregnancy. After birth, mother and infant are in good condition&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childbirth education classes help to prepare women, and their partners, for labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10311?source=see_link\">",
"     \"Preparation for labor and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional support of the patient during the birthing process may lower intrapartum analgesia requirements, decrease the rate of operative delivery, and increase patient satisfaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22855?source=see_link\">",
"     \"Continuous intrapartum support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Communication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The health care team should establish good communication with the parturient and the individuals who accompany her during labor and delivery. Good communication involves identifying the clinicians who will participate in her care (nurses, students, residents, attending physicians, anesthesiologists, and pediatricians), explaining all procedures, and keeping the parturient and her family informed about the maternal-fetal status. The team should involve the woman and her support person in management decisions, such as the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    to augment labor, the timing of amniotomy, intrapartum pain management, or the need for operative delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the initial physical examination of the parturient are to establish her baseline cervical status so that subsequent progress can be determined, to review her prenatal record for medical or obstetrical conditions which may need to be addressed (eg, pregestational diabetes mellitus, fetal abnormality, group B beta-hemolytic streptococcus [GBS] colonization), to check for development of new disorders (eg, bleeding, preeclampsia, chorioamnionitis), and to evaluate the fetal status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On admission to the labor unit, the patient's blood pressure, heart and respiratory rates, temperature, weight, and fetal heart rate (FHR) are recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/3\">",
"     3",
"    </a>",
"    ]. The quality of uterine contractions and their duration and frequency are also recorded (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Uterine contractions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    As discussed above, determining whether a woman is in labor is sometimes difficult as painful uterine contractions alone are not sufficient to establish a diagnosis of labor. Typically, the diagnosis is reserved for uterine contractions which result in cervical dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effacement. A recent history of bloody show (vaginal discharge of a small amount of blood and mucus [ie, mucus plug]) supports the diagnosis. Occasionally, fetal membranes rupture prior to the onset of labor.",
"   </p>",
"   <p>",
"    A physical examination is performed with particular emphasis on the cervical examination. The purpose of this examination is to determine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Whether the fetal membranes are intact or ruptured",
"      </strong>",
"      . Vaginal examinations are deferred if the membranes are ruptured and active labor has not ensued; a sterile speculum examination is performed in women with suspected membrane rupture to assess the cervix and confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4407?source=see_link\">",
"       \"Management of premature rupture of the fetal membranes at term\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the membranes have ruptured, the presence or absence of fetal meconium should be noted because of the possibility of meconium aspiration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21768?source=see_link\">",
"       \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Whether uterine bleeding is present and excessive",
"      </strong>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=see_link\">",
"       \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Cervical status",
"      </strong>",
"      :",
"      <br/>",
"      <br/>",
"      (1) Dilation (0 to 10 centimeters)",
"      <br/>",
"      <br/>",
"      (2) Effacement, described as zero (no effacement, the cervix is 3 to 4 cm long) to 100 percent (complete thinning of the cervix)",
"      <br/>",
"      <br/>",
"      (3) Fetal station, which should be expressed as the number of centimeters of the leading bony edge of the presenting part above or below the level of the ischial spines; the maximum denominator is 5 (eg, one centimeter beyond the ischial spines corresponds to",
"      <span class=\"nowrap\">",
"       +1/5",
"      </span>",
"      cm). Effacement and station are shown in the figures (",
"      <a class=\"graphic graphic_figure graphicRef58602 graphicRef67068 \" href=\"mobipreview.htm?26/38/27235\">",
"       figure 1A-B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      At this time, cervical status is best evaluated by digital examination, recognizing that inter- and intraobserver examinations are subjective and not highly reproducible. Automated devices for more objective and reproducible assessment are under investigation, but none have been proven to perform better than manual examination.",
"      <br/>",
"      <br/>",
"      An older system described fetal descent by dividing the distance from the ischial spines to pelvic outlet into thirds. Using this system, station",
"      <span class=\"nowrap\">",
"       +1/3",
"      </span>",
"      roughly corresponds to",
"      <span class=\"nowrap\">",
"       +2/5",
"      </span>",
"      cm in the centimeter system. This assessment has largely been abandoned because it is even more subjective than the centimeter system and makes it difficult to document small, but clinically significant, degrees of descent.",
"      <br/>",
"      <br/>",
"      If a cervical examination is not performed, fetal descent can also be described in terms of fifths of the fetal head palpable above the symphysis pubis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/4\">",
"       4",
"      </a>",
"      ]. This method is also useful if there is significant molding (change in shape of the fetal skull) or caput (edema of the portion of the fetal scalp overlying the cervical opening).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       The presentation and position of the fetus",
"      </strong>",
"      . Presentation refers to the part of the fetus at the cervical opening (eg, breech, vertex, shoulder) and position describes the relationship of the presenting part to the pelvis (eg, left occiput anterior) (",
"      <a class=\"graphic graphic_figure graphicRef81518 \" href=\"mobipreview.htm?16/32/16898\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef63528 graphicRef73262 graphicRef52247 \" href=\"mobipreview.htm?42/5/43093\">",
"       figure 3A-C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef57241 \" href=\"mobipreview.htm?24/39/25202\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef78180 \" href=\"mobipreview.htm?29/9/29840\">",
"       figure 5",
"      </a>",
"      ). If there is uncertainty, ultrasound examination can be useful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/5-7\">",
"       5-7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       The approximate size of the maternal pelvis",
"      </strong>",
"      (\"clinical pelvimetry\"). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26742?source=see_link&amp;anchor=H6#H6\">",
"       \"Mechanism of normal labor and delivery\", section on 'Passage (pelvis)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A urine specimen is tested for protein (proteinuria is one feature of preeclampsia), and blood is drawn for a complete blood count and",
"    <span class=\"nowrap\">",
"     ABO/Rh",
"    </span>",
"    blood typing. Although laboratory assessment of",
"    <span class=\"nowrap\">",
"     hemoglobin/hematocrit",
"    </span>",
"    and blood",
"    <span class=\"nowrap\">",
"     typing/screening",
"    </span>",
"    are commonly performed upon admission, there is no evidence that this practice is necessary in uncomplicated pregnancies. Relying on a normal hemoglobin result obtained at 26 to 28 weeks (eg, at the time of screening for gestational diabetes) and Rhesus (Rh) typing with a negative antibody screen obtained at the first prenatal visit appears to be a safe and acceptable approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. Typing and screening practices vary widely. A reasonable approach is to type and screen patients at moderate risk of needing a transfusion (eg, multiple gestation, trial of labor after cesarean,",
"    <span class=\"nowrap\">",
"     preeclampsia/HELLP",
"    </span>",
"    without coagulopathy, prior postpartum hemorrhage, grand multiparity) and type and cross patients at high risk of needing a transfusion (eg, placenta previa or accreta,",
"    <span class=\"nowrap\">",
"     preeclampsia/HELLP",
"    </span>",
"    with coagulopathy, severe anemia, congenital or acquired bleeding diathesis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who have not had HIV screening should be offered rapid HIV testing in labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. If the rapid test is positive, then antiretroviral prophylaxis should be initiated while confirmatory testing is being performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who were not screened for hepatitis B surface antigen prenatally, or engage in behaviors that put them at high risk for infection (eg, having had more than one sex partner in the previous six months, evaluation or treatment for an STD, recent or current injection-drug use, and an HBsAg-positive sex partner), or with clinical hepatitis should be retested at the time of hospital admission for delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/18\">",
"     18",
"    </a>",
"    ]. Shortened testing protocols can be used; the infant should receive immunoprophylaxis if the results are positive. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=see_link&amp;anchor=H13#H13\">",
"     \"Screening for sexually transmitted infections\", section on 'Hepatitis B'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=see_link&amp;anchor=H12#H12\">",
"     \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\", section on 'Hepatitis B vaccine and premature infants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In settings in which nucleic acid amplification tests (NAAT) such as PCR for GBS are available, obstetric providers can choose to perform intrapartum testing of vaginal-rectal samples from women with unknown GBS colonization status and no intrapartum risk factors (temperature &ge;100.4&ordm; F [&ge;38.0&ordm;C] or rupture of amniotic membranes &ge;18 hours) at the time of testing and who are delivering at term. Even if NAAT is negative, prophylaxis is suggested if a risk factor develops intrapartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link&amp;anchor=H4902960#H4902960\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Rapid diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABOR MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patient preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that routine enemas or perineal shaving is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. A urinary catheter is not necessary unless the woman is unable to void, but she should be encouraged to empty her bladder regularly. Although a full bladder sometimes appears to impede fetal descent, there is no evidence that it affects the course of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fluids and oral intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on acceptable maternal oral intake or need for intravenous fluids during an uncomplicated labor. A systematic review of five studies including over 3000 women in active labor and at low risk of potentially requiring a general anesthetic compared the outcome of women whose intake of",
"    <span class=\"nowrap\">",
"     food/fluids",
"    </span>",
"    was restricted to the outcome of women allowed nourishment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/25\">",
"     25",
"    </a>",
"    ]. Maternal and neonatal outcomes were similar in both groups; however, one important outcome, maternal satisfaction, was not assessed, and another important outcome, aspiration rate, could not be assessed because so few events occurred. The authors concluded that",
"    <span class=\"nowrap\">",
"     food/fluids",
"    </span>",
"    during labor should not be restricted in women at low risk of complications.",
"   </p>",
"   <p>",
"    Maternal oral intake of solids is often limited during active labor because of the risk of aspiration pneumonitis, a major cause of anesthetic-associated morbidity and mortality. Although this risk is very low in the current era, the American College of Obstetricians and Gynecologists and the American Society of Anesthesiologists Task Force on Obstetric Anesthesia recommend avoidance of solid foods in laboring women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors have suggested that since aspiration pneumonitis results from the acidity of the aspirated gastric contents, a clear antacid (eg, 10 to 30 mL sodium citrate) be administered to all women in labor; however, this has not been proven to be prevent aspiration and its consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/28\">",
"     28",
"    </a>",
"    ]. We do not routinely administer sodium citrate to our laboring patients, but give it to all patients before cesarean delivery. We do allow clear liquids to women at low risk of cesarean delivery who are in the active phase of labor.",
"   </p>",
"   <p>",
"    Insertion of an intravenous catheter provides immediate access for administration of drugs or blood in an emergency or for administration of drugs to augment labor, prevent or treat infection, and as prophylaxis or treatment of postpartum hemorrhage (see below). Intravenous access is advisable for fluid preloading if epidural or spinal anesthesia is to be used. We suggest placement of an intravenous line or a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    lock at the time admission laboratory tests are drawn. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interestingly, one randomized trial found that women who received intravenous hydration at 250",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    had fewer labors persisting for over 12 hours and less need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    augmentation than those who received 125",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/29\">",
"     29",
"    </a>",
"    ]. The authors postulated that inadequate hydration in labor may be a factor contributing to dysfunctional labor. However, these findings should be confirmed before laboring women are routinely prescribed large volumes of intravenous fluids because over-hydration can also be harmful. A study that evaluated the occurrence of hyponatremia among 287 Swedish women in labor found that 21 developed plasma sodium &le;130",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/30\">",
"     30",
"    </a>",
"    ]. Compared to women whose sodium concentration remained normal, women who developed hyponatremia were significantly more likely to have received a high volume of fluid (total oral and intravenous fluid volume over 2500 mL) and a high maximum oxytocin dose (20 to 60",
"    <span class=\"nowrap\">",
"     mU/min).",
"    </span>",
"    Two-thirds of the fluid intake was from oral hypotonic beverages. The authors did not document whether these women had symptoms of hyponatremia (eg, headache, nausea). In patients receiving oxytocin at higher doses (&gt;20",
"    <span class=\"nowrap\">",
"     mU/min)",
"    </span>",
"    or for prolonged periods (greater than 12 to 24 hours), it is important to be alert for signs of both hyponatremia as well as volume overload.",
"   </p>",
"   <p>",
"    The optimal crystalloid solution has not been determined, but some benefits have been reported for normal saline with 5 percent dextrose rather than without dextrose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infection prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapartum chemoprophylaxis to prevent early-onset neonatal GBS infection is indicated for appropriate patients; the agent of choice is intravenous penicillin. A minimum of four hours of intrapartum therapy has been recommended prior to delivery; however, bactericidal levels in cord blood are achieved within 30 minutes of administration to the mother so antibiotics should be administered even if delivery seems imminent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaginal or cesarean delivery is not an indication for routine antibiotic prophylaxis since the rate of bacteremia with these procedures is low. It reasonable to consider antibiotic prophylaxis against infective endocarditis before vaginal delivery at the time of membrane rupture in select patients with the highest risk of adverse outcomes (eg, prosthetic cardiac valve or prosthetic material used for cardiac valve repair, unrepaired or palliated cyanotic heart disease). These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link&amp;anchor=H15#H15\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Vaginal or cesarean delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Chlorhexidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to support the practice of intrapartum vaginal and cervical preparation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    wash or wipes for reducing the risk of maternal and neonatal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12459586\">",
"    <span class=\"h2\">",
"     Maternal activity and position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although walking during the first stage of labor is often recommended and may reduce patients' discomfort, it does not alter the duration of labor, the need for labor augmentation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , the use of analgesia, or the rate of assisted vaginal delivery and cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In addition to walking, sitting in a chair, showering, and baths may increase the comfort of the parturient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/38\">",
"     38",
"    </a>",
"    ]. Participation in these activities depends upon the maternal-fetal status, personal preference, and need for close monitoring. Maternal position in the first or second stage of labor does not significantly affect labor progress, thus women should be encouraged to assume whatever position is comfortable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12459650\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of pain during labor and delivery is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Monitoring and documentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients in labor should have an estimated fetal weight documented, either by ultrasound or clinical examination. All pregnant women require surveillance (eg, monitoring of vital signs and FHR) throughout labor and delivery as intrapartum complications can arise rapidly even in low risk women; 20 to 25 percent of all perinatal morbidity and mortality occurs in pregnancies with no underlying risk factors for adverse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/41\">",
"     41",
"    </a>",
"    ]. Assessment of the uterine contractions and cervical examinations are repeated at appropriate intervals to follow the progress of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Follow-up examinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard for the frequency of cervical examination, which should be kept to a minimum to avoid promoting intraamniotic infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link&amp;anchor=H5#H5\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Risk factors'",
"    </a>",
"    .) In general, vaginal examinations are performed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      On admission",
"     </li>",
"     <li>",
"      At one to four hour intervals in the first stage and at one hour intervals in the second stage",
"     </li>",
"     <li>",
"      Prior to intrapartum administration of analgesia",
"     </li>",
"     <li>",
"      When the parturient feels the urge to push to determine whether the cervix is fully dilated",
"     </li>",
"     <li>",
"      If FHR abnormalities occur to evaluate for conditions such as cord prolapse or uterine rupture",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fetal heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The labor admission test does not appear to be of value; it is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H17#H17\">",
"     \"Intrapartum fetal heart rate assessment\", section on 'Labor admission test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of routine continuous electronic fetal monitoring during labor is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The United States Preventive Services Task Force, the Canadian Task Force on Preventive Health Care, and others have made the following statements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine electronic fetal monitoring for low-risk women in labor is not mandatory.",
"     </li>",
"     <li>",
"      There is insufficient evidence to recommend for or against intrapartum electronic fetal monitoring for high-risk pregnant women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, some form of fetal heart rate assessment has become a standard of care for all women in the United States and will not be abandoned because patients and clinicians are reassured by normal results and believe there is some value in detecting abnormal patterns.",
"   </p>",
"   <p>",
"    In general, either manual auscultation or continuous electronic fetal monitoring is acceptable during labor. In practice in the United States, since current standards allow one nurse to care for two laboring until the second stage of labor, electronic fetal monitoring is more practical. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During the first stage of labor, we suggest that the FHR be checked at least every 15 minutes and recorded during and immediately after a contraction, when decelerations are most likely to occur. During the second stage of labor, we suggest that the FHR be checked at least every five minutes, and during and immediately after each uterine contraction. In general, continuous intrapartum FHR monitoring is suggested for high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/44\">",
"     44",
"    </a>",
"    ] and when FHR below 110 or over 160 beats per minute are detected.",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists suggests that electronic fetal monitoring tracings be reviewed every 30 minutes in the first stage of labor and every 15 minutes in the second stage in low risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/44\">",
"     44",
"    </a>",
"    ]. For higher risk patients, they suggest reviewing the tracing every 15 minutes in the first stage and every five minutes in the second stage. We suggest that review and assessment be documented in the patient's medical record.",
"   </p>",
"   <p>",
"    This documentation should include a description of uterine contractions, baseline FHR rate, baseline FHR variability, presence or absence of accelerations, presence or absence of periodic (ie, with contractions) or episodic (ie, unrelated to contractions) decelerations, and changes in the FHR over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Uterine contractions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine contractions are monitored to help in assessing labor progression and fetal heart rate patterns. Ninety-five percent of women in active labor will have three to five contractions per 10 minutes. Excessive uterine activity (hyperstimulation or tachysystole) is usually caused by administration of uterotonic drugs; noniatrogenic tachysystole is usually related to abruptio placenta or chorioamnionitis. Hypocontractile uterine activity may be due to drugs (including general or regional anesthesia), prolonged labor, fetopelvic disproportion, uterine rupture, chorioamnionitis, dehydration, and excessive uterine distention.",
"   </p>",
"   <p>",
"    Uterine activity can be assessed qualitatively by simple observation of the mother and palpation of the fundus of the uterus through the abdomen or by external tocodynamometry. Both methods provide good information on the frequency of contractions and an indication of their duration. Neither method accurately assesses contraction strength. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26742?source=see_link&amp;anchor=H4#H4\">",
"     \"Mechanism of normal labor and delivery\", section on 'Powers (uterine contractions)'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Maternal perception is influenced by whether the gravida has received analgesia, as well as the strength of the contraction, parity, and maternal weight: nulliparous and obese women may not perceive weak contractions. Contractions less than 15 mm Hg are not painful because they do not distend the lower uterine segment and cervix, thus they may not be perceived by the mother [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The ability to assess contractions by palpation is influenced by the thickness and tone of the abdominal wall and provider experience. External tocodynamometry is a convenient means for continuously recording contractions, but is affected by maternal movement (eg, breathing, coughing, vomiting, pushing, sitting, turning). The transducer has to be positioned correctly and the belt tightened appropriately to detect the change in shape of the uterus when it contracts. It works best when the mother is thin, doesn&rsquo;t move around much, and is partially supine. &nbsp;However, confining the parturient to her bed and restricting positional changes to better evaluate uterine contraction and fetal heart rate patterns is undesirable and only indicated when clinically necessary.",
"   </p>",
"   <p>",
"    Uterine activity can also be measured quantitatively by direct measurement of intrauterine pressure via internal tocodynamometry with pressure transducers. A large randomized trial that compared pregnancy outcome with internal versus external tocodynamometry demonstrated that both methods were equivalent in terms of operative delivery rates (cesarean, instrumental vaginal) and neonatal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/50\">",
"     50",
"    </a>",
"    ]. Given these data, external tocodynamometry is preferred since it is not associated with serious maternal or fetal morbidity.",
"   </p>",
"   <p>",
"    Although complications are uncommon, use of internal tocodynamometry can be associated with serious risks, including trauma to the placenta, umbilical cord, fetus, or uterus during insertion; maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal infection from introduction of a foreign body; and possibly anaphylactoid syndrome of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28053?source=see_link\">",
"     \"Insertion of intrauterine pressure catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Amniotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some providers artificially rupture intact fetal membranes after the diagnosis of labor is made to assess the quantity of fluid and the presence of meconium. A normal volume of clear amniotic fluid suggests that fetal acidosis is unlikely, assuming that delivery occurs within a short period of time and there are no sudden labor complications (eg, placental abruption, cord prolapse) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the presence of clear amniotic fluid does not diminish the need to evaluate fetuses with nonreassuring FHR patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine rupture of the membranes does not accelerate spontaneous labor. A systematic review of 14 randomized trials involving 4893 women compared the outcome of women managed with routine amniotomy versus those in whom preservation of intact membranes was planned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/53\">",
"     53",
"    </a>",
"    ]. Compared to the control group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amniotomy did not result in a significant reduction in the duration of the first stage of labor (weighted mean difference -20 minutes, 95% CI -96 to 55 minutes; five trials involving 1127 women).",
"     </li>",
"     <li>",
"      Amniotomy significantly reduced the risk of dysfunctional labor (RR 0.75, 95% CI 0.64-0.88; two trials involving 1005 women). However, there was no significant difference between groups in the rate of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      augmentation and a nonsignificant increase in cesarean delivery (RR 1.26, 95% CI 0.98-1.62). Thus, the statistical reduction in dysfunctional labor was not clinically advantageous.",
"     </li>",
"     <li>",
"      Amniotomy did not increase the risk of maternal infection or use of narcotic or epidural",
"      <span class=\"nowrap\">",
"       analgesia/anesthesia.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of this analysis was the lack of consistency in the timing of amniotomy with respect to cervical dilation. In addition, 20 to 60 percent of women assigned to the control group received an amniotomy at some stage in their labor.",
"   </p>",
"   <p>",
"    Another meta-analysis compared usual care to a policy of both early amniotomy and early",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    augmentation for women in normal spontaneous labor with mild delays in progress, and found that this combination of interventions was associated with a modest reduction in risk of cesarean delivery (RR 0.87, 95% CI 0.77-0.99, 11 trials, 7753 women) and shortened labor by about one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not perform routine amniotomy if labor is progressing well. We discourage routine amniotomy, even when progress is slow, if the head is not engaged. Amniotomy is indicated to further evaluate fetal status (eg, placement of a fetal scalp electrode) or uterine contractions (eg, placement of an intrauterine pressure catheter).",
"   </p>",
"   <p>",
"    If membranes are ruptured when there is polyhydramnios or an unengaged fetal presenting part, it is prudent to use a small gauge needle, rather than a hook, to puncture the fetal membranes in one or more places, and to perform the procedure in the operating room. This \"controlled amniotomy\" minimizes the risk of gushing amniotic fluid and permits emergency cesarean delivery in the event of an umbilical cord prolapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29494?source=see_link\">",
"     \"Umbilical cord prolapse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Amniotomy should be avoided, if possible, in women with active hepatitis B, hepatitis C, or HIV infection in order to minimize exposure of the fetus to ascending infection. Positive GBS carrier status, on the other hand, is not a contraindication to amniotomy, if indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12460401\">",
"    <span class=\"h2\">",
"     Normal progress of labor and labor abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing whether labor is progressing normally is a key component of intrapartum care; however, determining the onset of labor, measuring its progress, and evaluating the factors that affect its course (power, passenger, pelvis) is an inexact science. Criteria for normal and abnormal progress and management of protracted labor are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11306?source=see_link\">",
"     \"Abnormal labor: Protraction and arrest disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7160299\">",
"    <span class=\"h2\">",
"     Persistent anterior cervical lip",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final centimeter of cervix anteriorly between the pelvic brim and the fetal head usually rapidly disappears as the cervix fully dilates and the fetal head descends. An anterior lip that persists for greater than 30 minutes may be a variation of normal or may indicate a labor abnormality or malposition, such as occiput posterior presentation. An abnormality or malposition is more likely if the lip becomes edematous. Some authors suggest repositioning the parturient, monitoring labor progress, and exercising patience to see if the lip resolves over time. Others suggest manual reduction to avoid prolonged labor and the risk of cervical laceration, cervical necrosis, or detachment of the lip. We do not advise routine manual reduction of an anterior lip because of the risk of cervical injury and hemorrhage. This is especially true if the anterior lip does not reduce easily.",
"   </p>",
"   <p>",
"    The following procedure has been suggested for manual reduction of an anterior cervical lip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Place your fingers on the anterior lip where it touches the fetal head",
"     </li>",
"     <li>",
"      During a contraction, use your fingers to push the cervical lip backwards until it slips over the fetal head and above the interior border of the symphysis pubis",
"     </li>",
"     <li>",
"      Hold the cervical lip in this position while waiting for the next contraction.",
"     </li>",
"     <li>",
"      Allow your fingers, but not the cervix, to be pushed downwards and out as the fetal head descends with contractions and maternal pushing",
"     </li>",
"     <li>",
"      Remove your fingers when the cervix reduces or if the procedure is unsuccessful or poorly tolerated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous vaginal delivery is described below. Operative vaginal and abdominal delivery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=see_link\">",
"     \"Cesarean delivery: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Perineal massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antepartum and intrapartum perineal massage have been proposed as a means of softening and stretching the perineum to reduce perineal trauma during birth. Although not harmful, we do not routinely suggest or perform perineal massage as we feel there is insufficient high quality evidence proving a benefit.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review reported",
"      <strong>",
"       antepartum",
"      </strong>",
"      perineal massage performed at least weekly in the last month of pregnancy was associated with fewer episiotomies in women with no previous vaginal deliveries than in controls who did not undergo antepartum perineal massage (RR 0.85, 95% CI 0.75-0.97), but the frequency of perineal injury &ndash; ie,",
"      <span class=\"nowrap\">",
"       first/second",
"      </span>",
"      tears or",
"      <span class=\"nowrap\">",
"       third/fourth",
"      </span>",
"      degree trauma - was similar in both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of trials of",
"      <strong>",
"       intrapartum",
"      </strong>",
"      perineal interventions during the second stage reported use of warm compresses significantly reduced the rate of third and fourth degree tears (RR 0.48, 95% CI 0.28-0.84; two trials, 1525 women) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/57\">",
"       57",
"      </a>",
"      ]. Perineal massage was also associated with a significant reduction in the rate of third and fourth degree tears (RR 0.52, 95% CI 0.29-0.94; two trials, 2147 women). However, the methodologic quality of the trials varied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pushing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetric practice in the United States often dictates that the parturient begin pushing when the cervix attains full dilation (10 cm). However, some clinicians have questioned this practice and suggested delaying pushing until the presenting fetal part has descended",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the patient feels the urge to push. A meta-analysis of pooled data from 12 randomized trials of immediate versus delayed pushing found that delayed pushing resulted in a small but statistical increase in a woman's chance of having a spontaneous vaginal birth (61.5 versus 56.9 percent, RR 1.09, 95% CI 1.03-1.15), as well as prolongation of the second stage (mean difference 57 minutes, 95% CI 42 to 72 minutes) and less time pushing (mean difference -22 minutes, 95% CI -31 to -13 minutes), but did not lead to a statistical reduction in the rate of cesarean birth (4.9 versus 5.9 percent; RR 0.85, 95% CI 0.63-1.14) or instrumental delivery (33.7 versus 37.4 percent; RR 0.89, 95% CI 0.76-1.06) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/58\">",
"     58",
"    </a>",
"    ]. There were insufficient data on which to base conclusions about other clinically important maternal and neonatal outcomes. In addition, these findings may not apply to settings with much higher cesarean delivery rates (30 percent) and much lower instrumental delivery rates (5 percent), which are common in the United States.",
"   </p>",
"   <p>",
"    Given the available data, the decision to delay pushing can be based on patient specific factors, such as the need to expedite delivery (eg, in the presence of intraamniotic infection), maternal fatigue, and maternal preference. If the FHR tracing is reassuring and the head is high, we often delay pushing until the woman feels an urge to push.",
"   </p>",
"   <p>",
"    The optimum maternal position during pushing is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/59\">",
"     59",
"    </a>",
"    ]. Physiologic benefits postulated for an upright rather than recumbent position include the positive effect of gravity on the uterus, lessened risk of aortocaval compression and improved acid-base outcomes in the newborns, stronger and more efficient contractions, improved alignment of the fetus for passage through the pelvis, and an increase in pelvic dimensions (radiological evidence of larger anterior-posterior and transverse pelvic outlet diameters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/59\">",
"     59",
"    </a>",
"    ]. For women in an upright position, major outcomes appear to be similar whether kneeling or sitting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/60\">",
"     60",
"    </a>",
"    ]. We have the patient push in the position she finds most comfortable, but advise against the supine position.",
"   </p>",
"   <p>",
"    The optimum pushing technique is also unclear. Women are typically told to pull back their knees, tuck in their chin, take a deep breath, bear down at the start of a contraction, and push with a closed glottis (&ldquo;Valsalva pushing&rdquo;) for 10 seconds with the goal of three pushes per contraction. However, there is no evidence that coaching women in their expulsive efforts has any benefit over allowing the woman to bear down and push according to her own reflex needs in response to the pain of contractions and the pressure felt from descent of the fetal head [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/61\">",
"     61",
"    </a>",
"    ]. We generally favor allowing the patient to bear down when she feels the need (&ldquo;spontaneous pushing&rdquo; or &ldquo;physiological pushing&rdquo;), unless epidural anesthesia has impacted the bearing down sensation. We do not advise women to use Valsalva pushing, as there is no clinically significant benefit to this technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the presence of a reassuring FHR and continued progress, it is desirable for a nulliparous patient without regional anesthesia to push for as long as two hours (three hours with regional anesthesia) before resorting to interventions to facilitate delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/62\">",
"     62",
"    </a>",
"    ]. However, if there is continued progress and no evidence of maternal or fetal compromise, longer times are not associated with increased morbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11306?source=see_link\">",
"     \"Abnormal labor: Protraction and arrest disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Delivery site and maternal position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for spontaneous vaginal delivery should take into account the patient's parity, labor progression, fetal presentation, and complications of the labor. If it is anticipated that fetal manipulation may be necessary, such as with twin pregnancies or shoulder dystocia (see individual topic reviews on these subjects), we suggest transferring the patient to a delivery room equipped for emergency surgery. We also suggest encouraging delivery in the lithotomy position in these settings. Stirrups are not mandatory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If no complications are anticipated, delivery can be accomplished in an appropriately equipped labor room with the mother in almost any position that she finds comfortable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/59\">",
"     59",
"    </a>",
"    ]. Common positions include the lateral (Sims) position and the partial sitting position.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Episiotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of episiotomy in obstetric practice is decreasing. We suggest limiting this procedure to deliveries with a high risk of severe perineal laceration, soft tissue dystocia, or need to facilitate delivery of a possibly compromised fetus. There is no benefit to routine episiotomy at delivery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Delivery of the infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The responsibilities of the accoucheur are to reduce the risk of maternal perineal trauma, prevent fetal injury, and provide initial support of the newborn. There is no consensus regarding the best method of protecting the perineum at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/64-73\">",
"     64-73",
"    </a>",
"    ], other than avoiding routine episiotomy. Options include effecting delivery between contractions versus during a contraction, and various methods of using the accoucheur's hands to control delivery of the fetal head. The latter may involve no touch, passive perineal support, support of the fetal crown, and using fingers placed between the anus and coccyx to actively lift the fetal chin anteriorly (ie, Ritgen maneuver). Warm pads and perineal massage (see",
"    <a class=\"local\" href=\"#H24\">",
"     'Perineal massage'",
"    </a>",
"    above) have also been tried, with inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/70,72\">",
"     70,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given inconsistent data from observational studies and randomized trials, we use the following approach to prevent precipitous expulsion of the infant, which has been associated with tearing of the perineum:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We ask the woman to pant or make only small expulsive efforts when the head is fully crowning and delivery is imminent. This helps keep the head from tearing through the perineum.",
"     </li>",
"     <li>",
"      We place one hand on the vertex to maintain the head in a flexed position and control the speed of crowning",
"     </li>",
"     <li>",
"      We use the other hand to ease the perineum over the fetal head.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Avoiding midline episiotomy and avoiding delivery in a squatting or lithotomy position also appear to reduce the risk of anal sphincter laceration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=see_link\">",
"     \"Operative vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the fetal head is delivered, external rotation (restitution) occurs spontaneously. If the cord is around the neck (nuchal cord), slipping the cord over the head usually successfully frees the fetus from the tether. If a single nuchal cord is not reducible, we doubly clamp and transect it. Other options that have been described for a cord that is difficult to reduce but not tight include slipping it over the shoulders and delivering the baby's body through the loop, and delivering the body without reducing the cord (somersault maneuver). Mucus is gently wiped from the fetal nose and mouth.",
"   </p>",
"   <p>",
"    After delivery of the head, a hand is placed on each parietal eminence and the anterior shoulder is delivered with the next contraction, using gentle downward traction towards the mother's sacrum in concert with maternal expulsive efforts. In this way, the anterior shoulder is encouraged to slip under the symphysis pubis. The posterior shoulder is then delivered by upward traction. These movements should be performed with as little downward or upward force as possible to avoid perineal injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    traction injuries to the brachial plexus. The delivery is then completed, either spontaneously or with a gentle maternal push.",
"   </p>",
"   <p>",
"    The infant is wiped dry with a towel. There is no evidence that oronasopharyngeal suctioning by a bulb or catheter is beneficial in healthy term infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/76-80\">",
"     76-80",
"    </a>",
"    ] and, in some studies, suctioning slightly lowered neonatal oxygen saturation in the first few minutes of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/76,79,80\">",
"     76,79,80",
"    </a>",
"    ]. Suctioning immediately after birth is appropriate for babies with obvious obstruction due to secretions or who are likely to require positive-pressure ventilation. The mouth is suctioned first and then the nares to decrease the risk for aspiration (newborns are obligate nose breathers). Suctioning of the posterior pharynx should be avoided, as it can stimulate a vagal response, resulting in apnea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bradycardia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36105?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the routine management of the healthy newborn infant\", section on 'Delivery room care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early interaction between the mother and her infant should be encouraged by supporting skin-to-skin contact and early initiation of breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of postpartum care\", section on 'Delivery room'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Meconium",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of meconium, it had been common for obstetrical care providers to aspirate the upper airways on the perineum in an attempt to reduce the risk of meconium aspiration syndrome. However, randomized trials shown that this approach does",
"    <strong>",
"     NOT",
"    </strong>",
"    decrease meconium aspiration syndrome nor improve perinatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/81\">",
"     81",
"    </a>",
"    ]. Based on these data, the American Heart Association, the American Academy of Pediatrics, and the American College of Obstetricians and Gynecologists recommended against routine intrapartum suctioning of meconium-stained infants who are vigorous at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18648?source=see_link\">",
"     \"Prevention and management of meconium aspiration syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Cord clamping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, the timing of cord clamping was dictated by convenience and was usually performed within one minute of delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/84\">",
"     84",
"    </a>",
"    ]. There appears to be a rise in hemoglobin level in preterm and term infants when cord clamping is delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/85-89\">",
"     85-89",
"    </a>",
"    ] and when the infant is held below the level of the in situ placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Delayed (late) cord clamping is associated with significantly higher neonatal hematocrit levels even when the infant is placed on the mother&rsquo;s abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/92\">",
"     92",
"    </a>",
"    ]. No well designed randomized trials have specifically evaluated whether the location of the infant (above or below the level of the placenta) while the cord is intact significantly affects maternal or infant outcome or use of health resources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 75 percent of the blood available for placental to fetal transfusion is transfused in the first minute after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/91\">",
"     91",
"    </a>",
"    ]. The potential value of delayed cord clamping is a decrease in neonatal and infant anemia, but potentially at a cost of a higher rate of polycythemia and neonatal jaundice, as illustrated in the following meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Term infants",
"      </strong>",
"      &mdash; A meta-analysis of 11 randomized trials including 2989 mothers and their babies evaluated late (two to three minutes after birth) versus early cord clamping in term infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/94\">",
"       94",
"      </a>",
"      ]. Compared to early cord clamping, late cord clamping was associated with significantly higher hemoglobin levels in neonates and ferritin levels at six months of age, but also a significant increase in newborns needing phototherapy for jaundice (early versus late cord clamping RR 0.59, 95% CI 0.38-0.92; five trials 1762 infants). Delayed cord clamping halved the rate of anemia at ages 2 to 6 months (RR 0.53; 95% CI 0.40-0.70) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Preterm infants",
"      </strong>",
"      &mdash; A meta-analysis of 15 randomized trials evaluated late versus early cord clamping in 738 preterm infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/85\">",
"       85",
"      </a>",
"      ]. Compared to early cord clamping, late cord clamping was associated with fewer infants requiring transfusion for anemia (RR 0.61, 95% CI 0.46-0.81; seven trials, 392 infants), lower risk of necrotizing enterocolitis (RR 0.62, 95% CI 0.43-0.90; five trials, 241 infants), and fewer infants with any grade of intraventricular hemorrhage on ultrasound (RR 0.59, 95% CI 0.41-0.85; 10 trials, 539 infants). Peak bilirubin level was significantly higher with delayed cord clamping, but there was no significant increase in the need for treatment of jaundice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Higher infant iron stores may be particularly advantageous for infants of mothers with low ferritin levels, breastfed infants not receiving iron supplements or fortified formula, and preterm infants, but the increased need for phototherapy is an important disadvantage for infants who are at low risk of developing anemia. Late cord clamping may also be disadvantageous for growth restricted neonates who are at risk of polycythemia.",
"   </p>",
"   <p>",
"    Whether there is a clinical benefit from routine use of delayed cord clamping in all term deliveries is still unproven by high quality data; therefore, we agree with the American College of Obstetricians and Gynecologists (ACOG) committee opinion that the decision to perform early or delayed cord clamping be individualized in these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/95\">",
"     95",
"    </a>",
"    ]. In preterm infants, we agree with the ACOG committee&rsquo;s opinion that the significant reduction of intraventricular hemorrhage associated with delayed cord clamping is sufficiently compelling to adopt this intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6365163\">",
"    <span class=\"h3\">",
"     Cord milking",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an alternative to delayed clamping, the umbilical cord can be milked or stripped to enhance blood transfusion. This practice has been evaluated in few studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/96-100\">",
"     96-100",
"    </a>",
"    ], but there is some evidence that it helps to stabilize blood pressure and increase urinary output in premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/96,99\">",
"     96,99",
"    </a>",
"    ]. A randomized trial in preterm infants found that milking the cord four times was equivalent to delaying cord clamping for 30 seconds; both approaches resulted in similar hemoglobin values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A theoretical concern of cord milking is that a non-quantifiable amount of blood will be given to an immature infant in an uncontrolled fashion. Larger studies are needed to better evaluate the benefits and risks of this practice.",
"   </p>",
"   <p>",
"    At term, a randomized trial of early cord clamping with or without cord milking (three times at speed of 10",
"    <span class=\"nowrap\">",
"     cm/second)",
"    </span>",
"    reported cord milking resulted in significantly higher infant hemoglobin levels from 12 hours to 6 weeks after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/101\">",
"     101",
"    </a>",
"    ]. Serum bilirubin levels were also significantly higher, without a significant increase in the need for phototherapy for jaundice.",
"   </p>",
"   <p>",
"    Delivery should not be unnecessarily delayed to milk the cord in situations where immediate pediatric assistance is needed, such as thick meconium or neonatal depression. Also, it should not be done if cord blood collection is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cord blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord blood collected for diagnostic purposes is usually obtained by allowing blood to drain from the cut end into a glass tube prior to delivery of the placenta, if possible. Cord blood may be tested for blood type and Rh or to screen for a variety of newborn conditions, as indicated. Blood for pH testing is collected from the umbilical artery by a needle and syringe to minimize exposure to air and avoid mixing of arterial and venous blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Collection of cord blood for banking can be performed with a syringe before or after delivery of the placenta, but ex utero collection is preferred. The procedure for collection of umbilical cord blood for banking is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14958846\">",
"    <span class=\"h1\">",
"     THIRD STAGE OF LABOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third stage of labor is the interval from the birth of the baby to the expulsion of the placenta. There is no universally accepted criterion for the normal length of the third stage. Two large series of consecutive deliveries observed that the average length was five to six minutes, and that 90 percent of placentas were delivered within 15 minutes and 97 percent were delivered within 30 minutes of birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. The duration of the third stage of labor is important because the prevalence of postpartum hemorrhage increases as the duration lengthens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/102,104\">",
"     102,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gestational age is the major factor influencing the length of the third stage: preterm deliveries are associated with a longer third stage of labor than term deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/102,103,105,106\">",
"     102,103,105,106",
"    </a>",
"    ]. In one study, for example, the frequency of retained placenta was 20-fold higher in gestations &le;26 weeks and 3-fold higher in those less than 37 compared with term pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major complications of the third stage of labor are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhage (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"       \"Overview of postpartum hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41929?source=see_link\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Retained placenta (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35208?source=see_link\">",
"       \"Diagnosis and management of retained placenta after vaginal birth\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Uterine inversion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8743?source=see_link\">",
"       \"Puerperal uterine inversion\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14959330\">",
"    <span class=\"h2\">",
"     Normal placental separation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myometrial thickening after delivery of the infant leads to substantial reduction in uterine surface area, resulting in shearing forces at the placental attachment site and placental separation. This process generally begins at the lower pole of the placental margin and progresses along adjacent sites of placental attachment. A \"wave of separation\" spreads upwards so that the uppermost part of the placenta detaches last [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/107,108\">",
"     107,108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs of placental separation include a gush of blood, lengthening of the umbilical cord, and anterior-cephalad movement of the uterine fundus, which becomes firmer and globular after the placenta detaches. Placental expulsion follows separation as a result of a combination of events including spontaneous uterine contractions, downward pressure from the developing retroplacental hematoma, and an increase in maternal intraabdominal pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of postpartum care\", section on 'Uterine involution'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Active management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active management is the preferred approach to management of the third stage of labor. A meta-analysis comparing active versus expectant management of the third stage of labor found that active management was associated with reduced risks of maternal blood loss &gt;500 mL and &gt;1000 mL, but did not significantly reduce the length of the third stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=see_link&amp;anchor=H7#H7\">",
"     \"Uterotonic drugs for management of the third stage of labor\", section on 'Active management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Active management generally consists of prophylactic administration of an uterotonic agent before delivery of the placenta, typically with early cord",
"    <span class=\"nowrap\">",
"     clamping/cutting",
"    </span>",
"    and controlled traction of the umbilical cord; uterine massage also may be performed. The uterotonic agent is the most important component of this regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]. We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion into a maternal vein. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=see_link&amp;anchor=H9#H9\">",
"     \"Uterotonic drugs for management of the third stage of labor\", section on 'Oxytocin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence from randomized trials that uterine massage during the third stage significantly reduces blood loss at 30 and 60 minutes postpartum and reduces the need for additional uterotonic drugs, but a significant reduction in postpartum hemorrhage has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14959958\">",
"    <span class=\"h2\">",
"     Delivery of the placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled cord traction can be used to facilitate separation and delivery of the placenta. Although cord traction can shorten the third stage, it does not significantly reduce the volume of postpartum blood loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/111\">",
"     111",
"    </a>",
"    ], except possibly in settings where prophylactic uterotonic drugs are not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two maneuvers have been described: the Brandt-Andrews maneuver (an abdominal hand secures the uterine fundus to prevent uterine inversion while the other hand exerts sustained downward traction on the umbilical cord) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/113\">",
"     113",
"    </a>",
"    ], and the Cr&eacute;de maneuver (the cord is fixed with the lower hand while the uterine fundus is secured and sustained upward traction is applied using the abdominal hand). With both methods, care should be taken to avoid avulsion of the cord. We prefer the Brandt-Andrews maneuver.",
"   </p>",
"   <p>",
"    If the cord avulses before delivery of the placenta, we would wait up to 30 minutes for spontaneous placental separation and expulsion with maternal pushing. While waiting, preparations are initiated in case manual removal of the placenta is needed. We intervene promptly if bleeding becomes heavy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35208?source=see_link&amp;anchor=H6052644#H6052644\">",
"     \"Diagnosis and management of retained placenta after vaginal birth\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the placenta emerges from the vagina, the membranes flow behind it. Slowly rotating the placenta in circles as it is delivered or grasping the membranes with a clamp helps prevent them from tearing and possibly being retained in the uterine cavity.",
"   </p>",
"   <p>",
"    The placenta, umbilical cord, and fetal membranes should be systematically examined. The fetal side is assessed for any evidence of vessels coursing to the edge of the placenta and into the membranes, suggestive of a succenturiate placental lobe. The number of vessels in the cord is counted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=see_link\">",
"     \"Gross examination of the placenta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     BLOOD LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Average blood loss at delivery is generally estimated to be 500 mL. The obstetric care provider and nursing staff should be alert to excessive blood loss and should be prepared to intervene as required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     REPAIR OF LACERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cervix, vagina, and perineum should be carefully examined for evidence of birth injury. The major risk factors for third and fourth degree perineal lacerations are nulliparity, operative delivery, episiotomy, and delivery of a large for gestational age infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/21/33114/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a laceration is identified, its length and position should be noted and repair initiated. Adequate analgesia (either regional or local) is essential, otherwise exposure and operative technique may not be optimal. Special attention should be paid to repair of the perineal body, the external anal sphincter, and the rectal mucosa. Failure to recognize and repair rectal injury can lead to serious long-term morbidity, most notably urogenital prolapse with fecal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urinary incontinence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     POSTPARTUM ISSUES AND CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum issues and care, including care of the newborn, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=see_link\">",
"     \"Overview of postpartum care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       \"Patient information: Labor and delivery (childbirth) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/2/4131?source=see_link\">",
"       \"Patient information: How to tell when labor starts (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/5/33873?source=see_link\">",
"       \"Patient information: Managing pain during labor and delivery (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Key elements of labor management include good communication with and preparation and support of the patient, attention to her comfort, and regular assessment of both maternal and fetal status. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Psychosocial issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of the initial evaluation of the parturient are to establish her baseline cervical status, review her prenatal record, check for development of new intrapartum complications, and evaluate the fetal status. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have not had HIV screening should be offered rapid HIV testing in labor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Either manual auscultation of the fetal heart rate or continuous electronic fetal monitoring is acceptable. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Fetal heart rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not performing routine enemas (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) and we suggest not routinely shaving the perineum (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Patient preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus on acceptable maternal oral intake or need for intravenous fluids during an uncomplicated labor. We allow our low risk patients to have clear liquids. We suggest placement of an intravenous line or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      lock for all women in labor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Fluids and oral intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that all pregnant women with cardiac lesions susceptible to infective endocarditis receive antibiotic prophylaxis from the onset of active labor (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The American Heart Association recommends antibiotic prophylaxis for endocarditis in the presence of intraamniotic infection.",
"     </li>",
"     <li>",
"      The optimal pushing position technique, position, and duration are unclear. We suggest that the patient push in the position she finds most comfortable and with an open glottis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Pushing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend routine episiotomy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Episiotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine intrapartum suctioning of meconium-stained infants is unnecessary (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Meconium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend active management of the third stage of labor (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Active management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preterm births, we recommend delayed cord clamping (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For term infants, we suggest that the decision to perform early or delayed cord clamping or early cord clamping and cord milking be individualized, based on risk of anemia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Cord clamping'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The placenta should be examined to make sure it is intact. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Active management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/1\">",
"      Berghella V, Baxter JK, Chauhan SP. Evidence-based labor and delivery management. Am J Obstet Gynecol 2008; 199:445.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization, Maternal and Newborn Health/Safe Motherhood Unit. Care in normal birth: a practical guide. file://www.who.int/maternal_child_adolescent/documents/who_frh_msm_9624/en/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/3\">",
"      Pattinson RC. Pelvimetry for fetal cephalic presentations at term. Cochrane Database Syst Rev 2000; :CD000161.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Reproductive Health and Research. Managing Complications in Pregnancy and Childbirth. World Health Organization, Geneva, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/5\">",
"      Chou MR, Kreiser D, Taslimi MM, et al. Vaginal versus ultrasound examination of fetal occiput position during the second stage of labor. Am J Obstet Gynecol 2004; 191:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/6\">",
"      Kreiser D, Schiff E, Lipitz S, et al. Determination of fetal occiput position by ultrasound during the second stage of labor. J Matern Fetal Med 2001; 10:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/7\">",
"      Youssef A, Ghi T, Pilu G. How to perform ultrasound in labor: assessment of fetal occiput position. Ultrasound Obstet Gynecol 2013; 41:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/8\">",
"      Sherard GB 3rd, Newton ER. Is routine hemoglobin and hematocrit testing on admission to labor and delivery needed? Obstet Gynecol 2001; 98:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/9\">",
"      Ries LT, Kopelman JN, Macri CI. Evaluation of routine antepartum and postpartum blood counts. J Reprod Med 1998; 43:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/10\">",
"      Cousins LM, Teplick FB, Poeltler DM. Pre-cesarean blood bank orders: a safe and less expensive approach. Obstet Gynecol 1996; 87:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/11\">",
"      Ransom SB, Fundaro G, Dombrowski MP. Cost-effectiveness of routine blood type and screen testing for cesarean section. J Reprod Med 1999; 44:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/12\">",
"      Ransom SB, Fundaro G, Dombrowski MP. The cost-effectiveness of routine type and screen admission testing for expected vaginal delivery. Obstet Gynecol 1998; 92:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/13\">",
"      Palmer RH, Kane JG, Churchill WH, et al. Cost and quality in the use of blood bank services for normal deliveries, cesarean sections, and hysterectomies. JAMA 1986; 256:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/14\">",
"      Goodnough LT, Daniels K, Wong AE, et al. How we treat: transfusion medicine support of obstetric services. Transfusion 2011; 51:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/15\">",
"      ACOG Committee on Obstetric Practice. ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2004; 104:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/16\">",
"      Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004; 292:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/17\">",
"      American College of Obstetrics and Gynecology Committee on Obstetric Practice. ACOG Committee Opinion No. 418: Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations. Obstet Gynecol 2008; 112:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/18\">",
"      Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/19\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/20\">",
"      Cuervo LG, Rodr&iacute;guez MN, Delgado MB. Enemas during labor. Cochrane Database Syst Rev 2000; :CD000330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/21\">",
"      Cuervo LG, Bernal Mdel P, Mendoza N. Effects of high volume saline enemas vs no enema during labour--The N-Ma Randomised Controlled Trial [ISRCTN43153145]. BMC Pregnancy Childbirth 2006; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/22\">",
"      Basevi V, Lavender T. Routine perineal shaving on admission in labour. Cochrane Database Syst Rev 2001; :CD001236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/23\">",
"      Kerr-Wilson RH, Parham GP, Orr JW Jr. The effect of a full bladder on labor. Obstet Gynecol 1983; 62:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/24\">",
"      Read JA, Miller FC, Yeh S, Platt LD. Urinary bladder distention: effect on labor and uterine activity. Obstet Gynecol 1980; 56:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/25\">",
"      Singata M, Tranmer J, Gyte GM. Restricting oral fluid and food intake during labour. Cochrane Database Syst Rev 2010; :CD003930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/26\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 441: Oral intake during labor. Obstet Gynecol 2009; 114:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/27\">",
"      American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/28\">",
"      Gyte GM, Richens Y. Routine prophylactic drugs in normal labour for reducing gastric aspiration and its effects. Cochrane Database Syst Rev 2006; :CD005298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/29\">",
"      Garite TJ, Weeks J, Peters-Phair K, et al. A randomized controlled trial of the effect of increased intravenous hydration on the course of labor in nulliparous women. Am J Obstet Gynecol 2000; 183:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/30\">",
"      Moen V, Brudin L, Rundgren M, Irestedt L. Hyponatremia complicating labour--rare or unrecognised? A prospective observational study. BJOG 2009; 116:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/31\">",
"      Shrivastava VK, Garite TJ, Jenkins SM, et al. A randomized, double-blinded, controlled trial comparing parenteral normal saline with and without dextrose on the course of labor in nulliparas. Am J Obstet Gynecol 2009; 200:379.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/32\">",
"      Jamal A, Choobak N, Tabassomi F. Intrapartum maternal glucose infusion and fetal acid-base status. Int J Gynaecol Obstet 2007; 97:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/33\">",
"      Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther 2006; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/34\">",
"      Lumbiganon P, Thinkhamrop J, Thinkhamrop B, Tolosa JE. Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV). Cochrane Database Syst Rev 2004; :CD004070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/35\">",
"      Cutland CL, Madhi SA, Zell ER, et al. Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet 2009; 374:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/36\">",
"      Bloom SL, McIntire DD, Kelly MA, et al. Lack of effect of walking on labor and delivery. N Engl J Med 1998; 339:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/37\">",
"      Roberts CL, Algert CS, Olive E. Impact of first-stage ambulation on mode of delivery among women with epidural analgesia. Aust N Z J Obstet Gynaecol 2004; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/38\">",
"      Cluett ER, Nikodem VC, McCandlish RE, Burns EE. Immersion in water in pregnancy, labour and birth. Cochrane Database Syst Rev 2004; :CD000111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/39\">",
"      Lawrence A, Lewis L, Hofmeyr GJ, et al. Maternal positions and mobility during first stage labour. Cochrane Database Syst Rev 2009; :CD003934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/40\">",
"      Kemp E, Kingswood CJ, Kibuka M, Thornton JG. Position in the second stage of labour for women with epidural anaesthesia. Cochrane Database Syst Rev 2013; 1:CD008070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/41\">",
"      Zapata-V&aacute;zquez RE, Rodr&iacute;guez-Carvajal LA, Sierra-Basto G, et al. Discriminant function of perinatal risk that predicts early neonatal morbidity: its validity and reliability. Arch Med Res 2003; 34:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/42\">",
"      Vintzileos AM, Nochimson DJ, Antsaklis A, et al. Comparison of intrapartum electronic fetal heart rate monitoring versus intermittent auscultation in detecting fetal acidemia at birth. Am J Obstet Gynecol 1995; 173:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/43\">",
"      Young BK. Monitoring the fetal heart: a continuing controversy. Obstet Gynecol Surv 1995; 50:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/44\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists, Number 70, December 2005 (Replaces Practice Bulletin Number 62, May 2005). Intrapartum fetal heart rate monitoring. Obstet Gynecol 2005; 106:1453.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Preventive Services Task Force. Screening: Intrapartum Electronic Fetal Monitoring, 1996. www.ahcpr.gov/clinic/uspstf/uspsiefm.htm (Accessed 3/10/05).",
"    </li>",
"    <li>",
"     Canadian Task Force on Preventive Care. www.ctfphc.org/ (Accessed 3/10/05).",
"    </li>",
"    <li>",
"     Midwives Information and Resource Service (UK). www.midirs.org/nelh/nelh.nsf/ICNVIEW/2p1. (Accessed 3/10/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/48\">",
"      Chan WH, Paul RH, Toews J. Intrapartum fetal monitoring. Maternal and fetal morbidity and perinatal mortality. Obstet Gynecol 1973; 41:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/49\">",
"      Bakker PC, Van Rijswijk S, Van Rijsiwijk S, van Geijn HP. Uterine activity monitoring during labor. J Perinat Med 2007; 35:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/50\">",
"      Bakker JJ, Verhoeven CJ, Janssen PF, et al. Outcomes after internal versus external tocodynamometry for monitoring labor. N Engl J Med 2010; 362:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/51\">",
"      Locatelli A, Regalia AL, Patregnani C, et al. Prognostic value of change in amniotic fluid color during labor. Fetal Diagn Ther 2005; 20:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/52\">",
"      Greenwood C, Lalchandani S, MacQuillan K, et al. Meconium passed in labor: how reassuring is clear amniotic fluid? Obstet Gynecol 2003; 102:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/53\">",
"      Smyth RM, Alldred SK, Markham C. Amniotomy for shortening spontaneous labour. Cochrane Database Syst Rev 2007; :CD006167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/54\">",
"      Wei S, Wo BL, Qi HP, et al. Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care. Cochrane Database Syst Rev 2012; 9:CD006794.",
"     </a>",
"    </li>",
"    <li>",
"     Varney, H. Varney's Midwifery, 3rd, Jones and Bartlett, Boston 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/56\">",
"      Beckmann MM, Garrett AJ. Antenatal perineal massage for reducing perineal trauma. Cochrane Database Syst Rev 2006; :CD005123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/57\">",
"      Aasheim V, Nilsen A, Lukasse M, Reinar LM. Perineal techniques during the second stage of labour for reducing perineal trauma. Cochrane Database Syst Rev 2011; :CD006672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/58\">",
"      Tuuli MG, Frey HA, Odibo AO, et al. Immediate compared with delayed pushing in the second stage of labor: a systematic review and meta-analysis. Obstet Gynecol 2012; 120:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/59\">",
"      Gupta JK, Hofmeyr GJ, Shehmar M. Position in the second stage of labour for women without epidural anaesthesia. Cochrane Database Syst Rev 2012; 5:CD002006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/60\">",
"      Ragnar I, Altman D, Tyd&eacute;n T, Olsson SE. Comparison of the maternal experience and duration of labour in two upright delivery positions--a randomised controlled trial. BJOG 2006; 113:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/61\">",
"      Prins M, Boxem J, Lucas C, Hutton E. Effect of spontaneous pushing versus Valsalva pushing in the second stage of labour on mother and fetus: a systematic review of randomised trials. BJOG 2011; 118:662.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Dystocia and augmentation of labor. ACOG Practice Bulletin # 49, American College of Obstetricians and Gynecologists, Washington, DC 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/63\">",
"      Corton MM, Lankford JC, Ames R, et al. A randomized trial of birthing with and without stirrups. Am J Obstet Gynecol 2012; 207:133.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/64\">",
"      Laine K, Pirhonen T, Rolland R, Pirhonen J. Decreasing the incidence of anal sphincter tears during delivery. Obstet Gynecol 2008; 111:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/65\">",
"      Parnell C, Langhoff-Roos J, M&oslash;ller H. Conduct of labor and rupture of the sphincter ani. Acta Obstet Gynecol Scand 2001; 80:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/66\">",
"      Samuelsson E, Ladfors L, Wennerholm UB, et al. Anal sphincter tears: prospective study of obstetric risk factors. BJOG 2000; 107:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/67\">",
"      Pirhonen JP, Grenman SE, Haadem K, et al. Frequency of anal sphincter rupture at delivery in Sweden and Finland--result of difference in manual help to the baby's head. Acta Obstet Gynecol Scand 1998; 77:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/68\">",
"      McCandlish R, Bowler U, van Asten H, et al. A randomised controlled trial of care of the perineum during second stage of normal labour. Br J Obstet Gynaecol 1998; 105:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/69\">",
"      Mayerhofer K, Bodner-Adler B, Bodner K, et al. Traditional care of the perineum during birth. A prospective, randomized, multicenter study of 1,076 women. J Reprod Med 2002; 47:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/70\">",
"      Dahlen HG, Homer CS, Cooke M, et al. Perineal outcomes and maternal comfort related to the application of perineal warm packs in the second stage of labor: a randomized controlled trial. Birth 2007; 34:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/71\">",
"      J&ouml;nsson ER, Elfaghi I, Rydhstr&ouml;m H, Herbst A. Modified Ritgen's maneuver for anal sphincter injury at delivery: a randomized controlled trial. Obstet Gynecol 2008; 112:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/72\">",
"      Albers LL, Sedler KD, Bedrick EJ, et al. Midwifery care measures in the second stage of labor and reduction of genital tract trauma at birth: a randomized trial. J Midwifery Womens Health 2005; 50:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/73\">",
"      Hals E, Oian P, Pirhonen T, et al. A multicenter interventional program to reduce the incidence of anal sphincter tears. Obstet Gynecol 2010; 116:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/74\">",
"      Gottvall K, Allebeck P, Ek&eacute;us C. Risk factors for anal sphincter tears: the importance of maternal position at birth. BJOG 2007; 114:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/75\">",
"      Carroli G, Belizan J. Episiotomy for vaginal birth. Cochrane Database Syst Rev 2000; :CD000081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/76\">",
"      Carrasco M, Martell M, Estol PC. Oronasopharyngeal suction at birth: effects on arterial oxygen saturation. J Pediatr 1997; 130:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/77\">",
"      Waltman PA, Brewer JM, Rogers BP, May WL. Building evidence for practice: a pilot study of newborn bulb suctioning at birth. J Midwifery Womens Health 2004; 49:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/78\">",
"      Estol PC, Piriz H, Basalo S, et al. Oro-naso-pharyngeal suction at birth: effects on respiratory adaptation of normal term vaginally born infants. J Perinat Med 1992; 20:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/79\">",
"      Gungor S, Teksoz E, Ceyhan T, et al. Oronasopharyngeal suction versus no suction in normal, term and vaginally born infants: a prospective randomised controlled trial. Aust N Z J Obstet Gynaecol 2005; 45:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/80\">",
"      Gungor S, Kurt E, Teksoz E, et al. Oronasopharyngeal suction versus no suction in normal and term infants delivered by elective cesarean section: a prospective randomized controlled trial. Gynecol Obstet Invest 2006; 61:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/81\">",
"      Vain NE, Szyld EG, Prudent LM, et al. Oropharyngeal and nasopharyngeal suctioning of meconium-stained neonates before delivery of their shoulders: multicentre, randomised controlled trial. Lancet 2004; 364:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/82\">",
"      American Heart Association. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: pediatric basic life support. Pediatrics 2006; 117:e989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/83\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 379: Management of delivery of a newborn with meconium-stained amniotic fluid. Obstet Gynecol 2007; 110:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/84\">",
"      Lainez Villabona B, Bergel Ayllon E, Cafferata Thompson ML, Beliz&aacute;n Chiesa JM. [Early or late umbilical cord clamping? A systematic review of the literature]. An Pediatr (Barc) 2005; 63:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/85\">",
"      Rabe H, Diaz-Rossello JL, Duley L, Dowswell T. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev 2012; 8:CD003248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/86\">",
"      Ceriani Cernadas JM, Carroli G, Pellegrini L, et al. The effect of timing of cord clamping on neonatal venous hematocrit values and clinical outcome at term: a randomized, controlled trial. Pediatrics 2006; 117:e779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/87\">",
"      Chaparro CM, Neufeld LM, Tena Alavez G, et al. Effect of timing of umbilical cord clamping on iron status in Mexican infants: a randomised controlled trial. Lancet 2006; 367:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/88\">",
"      Strauss RG, Mock DM, Johnson KJ, et al. A randomized clinical trial comparing immediate versus delayed clamping of the umbilical cord in preterm infants: short-term clinical and laboratory endpoints. Transfusion 2008; 48:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/89\">",
"      Sommers R, Stonestreet BS, Oh W, et al. Hemodynamic effects of delayed cord clamping in premature infants. Pediatrics 2012; 129:e667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/90\">",
"      Mercer JS, Vohr BR, McGrath MM, et al. Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial. Pediatrics 2006; 117:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/91\">",
"      Yao AC, Lind J. Effect of gravity on placental transfusion. Lancet 1969; 2:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/92\">",
"      Hutton EK, Hassan ES. Late vs early clamping of the umbilical cord in full-term neonates: systematic review and meta-analysis of controlled trials. JAMA 2007; 297:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/93\">",
"      Airey RJ, Farrar D, Duley L. Alternative positions for the baby at birth before clamping the umbilical cord. Cochrane Database Syst Rev 2010; :CD007555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/94\">",
"      McDonald SJ, Middleton P. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database Syst Rev 2008; :CD004074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/95\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. Committee Opinion No.543: Timing of umbilical cord clamping after birth. Obstet Gynecol 2012; 120:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/96\">",
"      Hosono S, Mugishima H, Fujita H, et al. Umbilical cord milking reduces the need for red cell transfusions and improves neonatal adaptation in infants born at less than 29 weeks' gestation: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2008; 93:F14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/97\">",
"      SIDDALL RS, RICHARDSON RP. Milking or stripping the umbilical cord; effect on vaginally delivered babies. Obstet Gynecol 1953; 1:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/98\">",
"      SIDDALL RS, CRISSEY RR, KNAPP WL. Effect on cesarean section babies of stripping or milking of the umbilical cords. Am J Obstet Gynecol 1952; 63:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/99\">",
"      Hosono S, Mugishima H, Fujita H, et al. Blood pressure and urine output during the first 120 h of life in infants born at less than 29 weeks' gestation related to umbilical cord milking. Arch Dis Child Fetal Neonatal Ed 2009; 94:F328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/100\">",
"      Rabe H, Jewison A, Alvarez RF, et al. Milking compared with delayed cord clamping to increase placental transfusion in preterm neonates: a randomized controlled trial. Obstet Gynecol 2011; 117:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/101\">",
"      Upadhyay A, Gothwal S, Parihar R, et al. Effect of umbilical cord milking in term and near term infants: randomized control trial. Am J Obstet Gynecol 2013; 208:120.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/102\">",
"      Dombrowski MP, Bottoms SF, Saleh AA, et al. Third stage of labor: analysis of duration and clinical practice. Am J Obstet Gynecol 1995; 172:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/103\">",
"      Combs CA, Laros RK Jr. Prolonged third stage of labor: morbidity and risk factors. Obstet Gynecol 1991; 77:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/104\">",
"      HIBBARD BM. OBSTETRICS IN GENERAL PRACTICE. THE THIRD STAGE OF LABOUR. Br Med J 1964; 1:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/105\">",
"      Romero R, Hsu YC, Athanassiadis AP, et al. Preterm delivery: a risk factor for retained placenta. Am J Obstet Gynecol 1990; 163:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/106\">",
"      Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertil Steril 1986; 45:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/107\">",
"      Herman A, Weinraub Z, Bukovsky I, et al. Dynamic ultrasonographic imaging of the third stage of labor: new perspectives into third-stage mechanisms. Am J Obstet Gynecol 1993; 168:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/108\">",
"      Herman A. Complicated third stage of labor: time to switch on the scanner. Ultrasound Obstet Gynecol 2000; 15:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/109\">",
"      Begley CM, Gyte GM, Devane D, et al. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev 2011; :CD007412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/110\">",
"      Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2008; :CD006431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/111\">",
"      G&uuml;lmezoglu AM, Lumbiganon P, Landoulsi S, et al. Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet 2012; 379:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/112\">",
"      Sheldon WR, Durocher J, Winikoff B, et al. How effective are the components of active management of the third stage of labor? BMC Pregnancy Childbirth 2013; 13:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/113\">",
"      Brandt ML. The mechanism and management of the third stage of labor. Am J Obstet Gynecol 1936; 25:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/21/33114/abstract/114\">",
"      Landy HJ, Laughon SK, Bailit JL, et al. Characteristics associated with severe perineal and cervical lacerations during vaginal delivery. Obstet Gynecol 2011; 117:627.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4445 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.147-B9BF6B98CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33114=[""].join("\n");
var outline_f32_21_33114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3729454\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PSYCHOSOCIAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Communication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABOR MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patient preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fluids and oral intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infection prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Chlorhexidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12459586\">",
"      Maternal activity and position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12459650\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Monitoring and documentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Follow-up examinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fetal heart rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Uterine contractions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Amniotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12460401\">",
"      Normal progress of labor and labor abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7160299\">",
"      Persistent anterior cervical lip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Perineal massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pushing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Delivery site and maternal position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Episiotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Delivery of the infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Meconium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Cord clamping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6365163\">",
"      - Cord milking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cord blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14958846\">",
"      THIRD STAGE OF LABOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14959330\">",
"      Normal placental separation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Active management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14959958\">",
"      Delivery of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BLOOD LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      REPAIR OF LACERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      POSTPARTUM ISSUES AND CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4445|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/22/44399\" title=\"figure 1A\">",
"      Effacement and dilatation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/54/19311\" title=\"figure 1B\">",
"      Fetal station",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/32/16898\" title=\"figure 2\">",
"      Fontanelles and suture lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/30/28143\" title=\"figure 3A\">",
"      Occiput anterior position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/52/32590\" title=\"figure 3B\">",
"      Occiput posterior position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/0/32783\" title=\"figure 3C\">",
"      Occiput transverse position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/39/25202\" title=\"figure 4\">",
"      Occiput posterior and occiput transverse positions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/9/29840\" title=\"figure 5\">",
"      Longitudinal lie cephalic presentation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14682?source=related_link\">",
"      Cesarean delivery: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/20/22855?source=related_link\">",
"      Continuous intrapartum support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35208?source=related_link\">",
"      Diagnosis and management of retained placenta after vaginal birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/27/38326?source=related_link\">",
"      Face and brow presentations in labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=related_link\">",
"      Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28053?source=related_link\">",
"      Insertion of intrauterine pressure catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4407?source=related_link\">",
"      Management of premature rupture of the fetal membranes at term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26742?source=related_link\">",
"      Mechanism of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/39/15994?source=related_link\">",
"      Operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/8/13448?source=related_link\">",
"      Overview of breech presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/2/4131?source=related_link\">",
"      Patient information: How to tell when labor starts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/5/33873?source=related_link\">",
"      Patient information: Managing pain during labor and delivery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10311?source=related_link\">",
"      Preparation for labor and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/13/18648?source=related_link\">",
"      Prevention and management of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8743?source=related_link\">",
"      Puerperal uterine inversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35702?source=related_link\">",
"      Umbilical cord blood acid-base analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/51/29494?source=related_link\">",
"      Umbilical cord prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=related_link\">",
"      Uterotonic drugs for management of the third stage of labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_21_33115="Risk factors ICH warfarin";
var content_f32_21_33115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76220&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for intracerebral hemorrhage during warfarin anticoagulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Firmly established risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advancing age (especially &gt;75 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension (especially systolic blood pressure &gt;160 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of cerebrovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intensity of anticoagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concomitant use of aspirin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral amyloid angiopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asian or Mexican-American ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heavy alcohol consumption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Imaging and genetic markers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukoaraiosis detected by brain CT/MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microbleeds by T2*-weighted MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        APOE epsilon II or IV genotype",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36:1588. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33115=[""].join("\n");
var outline_f32_21_33115=null;
var title_f32_21_33116="Increase in infant blood lead concentration from breast milk";
var content_f32_21_33116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated* increase in infant blood lead concentration&bull; associated with different maternal blood lead concentrations at 1 month postpartum",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Maternal blood lead concentration, &micro;g/dL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated breast milk lead concentration, &micro;g/L",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated associated increase in infant blood lead at age 1 month, &micro;g/dL&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        0.49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        0.62",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"       <td>",
"        0.98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40&loz;",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This estimation integrates absorption, distribution, and excretion.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      These values are estimations based upon ICP-MS laboratory analysis and increments of less than 2 &mu;g/dL would not necessarily be detectable in clinical laboratories.",
"      <br>",
"       &Delta; Calculated based upon the observation that a 2 &mu;g/L increase in breast milk lead is associated with an increase of 0.82 &mu;g/dL in the blood lead of the nursing infant (Ettinger et al. 2004b",
"       <sup>",
"        [1]",
"       </sup>",
"       ).",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Extrapolation beyond the range of observed data from Ettinger et al. 2004b",
"        <sup>",
"         [1]",
"        </sup>",
"        (where maternal BLLs ranged from 1-30 &mu;g/dL).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <ol>",
"      <li>",
"       Ettinger AS, Tellez-Rojo MM, Amarasiriwardena C, Bellinger D, Peterson K, Schwartz J, et al. 2004b. Effect of breast milk lead on infant blood lead levels at 1 month of age. Environ Health Perspect 112(14):1381-5.",
"      </li>",
"     </ol>",
"     <br>",
"      Reproduced from: Ettinger AS, Gurthrie Wengrovitz A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at",
"      <a href=\"file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\">",
"       file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf",
"      </a>",
"      .",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33116=[""].join("\n");
var outline_f32_21_33116=null;
var title_f32_21_33117="Expired NO in asthma";
var content_f32_21_33117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Expired NO in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histogram showing the distribution of mixed expired NO in a group of nonsmoking normal subjects (red bars; n=90, 58 female, age range 19 to 65) and patients with asthma (blue bars; n=43, 27 female, age range 20 to 88). The mean mixed expired NO content was significantly lower in normal subjects than in patients with asthma (6.2 versus 13.9 ppb).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Massaro, AF, Gaston, B, Kita, D, et al, Am J Respir Crit Care Med 1995; 152:800.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33117=[""].join("\n");
var outline_f32_21_33117=null;
var title_f32_21_33118="AC osteoarthritis plain xray";
var content_f32_21_33118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acromioclavicular osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain x-ray demonstrates inferiorly directed osteophytes consistent with acromioclavicular (AC) osteoarthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33118=[""].join("\n");
var outline_f32_21_33118=null;
var title_f32_21_33119="APL hypergranular variant";
var content_f32_21_33119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypergranular variant of acute promyelocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The malignant promyelocytes in the more common \"hypergranular\" variant of acute promyelocytic leukemia (APL) have characteristic large reddish-blue or dark purple granules in the cytoplasm. The nucleus is often folded, indented, or dumb-bell shaped.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard A Larson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_21_33119=[""].join("\n");
var outline_f32_21_33119=null;
